<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2306210824
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2011
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SEROXAT 20MG TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PAROXETINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        60.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DELPHARM POZNAN SPOLKA AKCYJNA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DELPHARM POZNAN SPOLKA AKCYJNA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1182]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            GLAXO SAUDI ARABIA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GLAXO SAUDI ARABIA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient in Seroxat is paroxetine, which belongs to a group of medicines called SSRIs (<em>selective serotonin reuptake inhibitors</em>). In adults aged 18 years and over Seroxat is used to treat:</p><p>&middot;&nbsp;&nbsp;&nbsp; major depressive disorder</p><p>&middot;&nbsp;&nbsp;&nbsp; obsessive compulsive disorder</p><p>&middot;&nbsp;&nbsp;&nbsp; panic attacks, including those caused by a fear of open spaces (<em>agoraphobia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp; general anxiety or anxiety caused by situations such as socialising or performance</p><p>&middot;&nbsp;&nbsp;&nbsp; anxiety following a traumatic event (<em>Post-traumatic Stress Disorder</em>)</p><p>&nbsp;</p><p>These conditions can occur when the amount of a substance called serotonin in the brain is reduced. Paroxetine works by increasing serotonin levels in the brain.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Don&rsquo;t take Seroxat</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic </strong>(<em>hypersensitive</em>) to paroxetine or any other ingredients of Seroxat (listed in Section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking or have recently taken (within the last two weeks) <strong>medicines for depression </strong>called <strong>monoamine oxidase inhibitors (MAOIs)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking or have recently taken (within the last two weeks) an <strong>antibiotic </strong>medicine called <strong>linezolid</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking or have recently taken (within the last two weeks) a medicine called methylthioninium chloride (<strong>methylene blue</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking <strong>medicines called thioridazine or pimozide </strong>(usually used to treat schizophrenia)</p><p>&Uacute; If you think any of these apply to you, <strong>don&rsquo;t take Seroxat </strong>until you have checked with your doctor.</p><p>&nbsp;</p><p><strong>Take special care with Seroxat</strong><!--[if supportFields]><span style='mso-bookmark:
_Hlk46059407'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk46059407'><b><span style='font-size:13.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:Arial;mso-bidi-font-family:
Arial;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:
EN-GB'> DOCVARIABLE vault_nd_45c40835-da47-4eec-8fd9-88dc1f0a349f \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span></b></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-end'></span><![endif]--></p><p><strong>Seroxat is not recommended for people aged under18. </strong>The effectiveness of Seroxat has not been demonstrated in this age group. Medicines used to treat depression and other mental health problems may increase the risk of suicidal thoughts and behaviour in children and adolescents aged under 18 years. There is no information on the long-term safety of Seroxat in this age group.</p><p>&nbsp;</p><p><strong>Before you take Seroxat your doctor needs to know:</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk46059407'><b><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'> DOCVARIABLE
vault_nd_a242d8a9-3c26-4e07-a62b-1a948fe1e075 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-end'></span><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp; if you have taken <strong>medicines for depression called MAOIs </strong>and the date you stopped taking them</p><p>&middot;&nbsp;&nbsp;&nbsp; if you have taken an antibiotic called <strong>linezolid </strong>and the date you stopped it</p><p>&middot;&nbsp;&nbsp;&nbsp; if you are taking <strong>tamoxifen </strong>(used to treat or prevent breast cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp; if you have ever had <strong>episodes of hyperactivity, elation and irritability </strong><em>(mania)</em></p><p>&middot;&nbsp;&nbsp;&nbsp; if you have ever had <strong>periods of mania alternating with periods of depression </strong>(<em>bipolar mood disorder</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp; if you have <strong>kidney or liver disease</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; if you have <strong>heart disease </strong></p><p>&middot;&nbsp;&nbsp;&nbsp; if your<strong> heart tracing (electrocardiogram/ECG) has an abnormality known as prolonged QT interval </strong>or you are taking medicines that may affect the QT interval in the ECG</p><p>&middot;&nbsp;&nbsp;&nbsp; if you have <strong>epilepsy</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; if you suffer from <strong>glaucoma </strong>(a condition caused by raised pressure in the eye)</p><p>&middot;&nbsp;&nbsp;&nbsp; if you have a history of <strong>bleeding problems</strong>, or are taking medicines that increase your risk of bleeding</p><p>&Uacute; <strong>Check with your doctor </strong>if you think any of these may apply to you. Your doctor will decide whether Seroxat is suitable for you, or if you need extra check-ups</p><p>&nbsp;</p><p><strong>Thoughts of suicide or worsening of your condition</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk46059407'><b><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'> DOCVARIABLE
vault_nd_d3303716-b5c1-492a-8c6e-19e4b7dc8b5b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-end'></span><![endif]--></p><p>If you are depressed, you may sometimes have suicidal thoughts or thoughts of harming yourself. Since medicines like Seroxat take time to work (usually about 2 weeks, but sometimes longer), suicidal thoughts or thoughts of harming yourself may continue or increase, particularly when you start taking Seroxat.</p><p>You may be more likely to think like this if you:</p><p>&middot;&nbsp;&nbsp;&nbsp; are a young adult</p><p>&middot;&nbsp;&nbsp;&nbsp; have previously had thoughts of this nature</p><p>&middot;&nbsp;&nbsp;&nbsp; have recently had a change in dose.</p><p>If you have distressing thoughts or experiences, or if you notice that you feel worse or develop new symptoms while you&rsquo;re taking Seroxat:</p><p>&Uacute; <strong>Contact your doctor or go to a hospital straight away.</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk46059407'><b><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'> DOCVARIABLE
vault_nd_9da652ac-7fd2-45ee-a825-a3835481323e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>You may find it helpful to tell a relative or close friend </strong>that you are depressed, and ask them to read this leaflet. You might ask them to tell you if they think your depression is getting worse, or if they are worried about changes in your behaviour.</p><p><strong>&nbsp;</strong></p><p><strong>Conditions you need to look out for</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk46059407'><b><span style='font-size:13.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:Arial;mso-bidi-font-family:
Arial;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:
EN-GB'> DOCVARIABLE vault_nd_0343e286-1720-4428-87b7-e200b3b635a8 \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span></b></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-end'></span><![endif]--></p><p>Medicines like Seroxat used to treat mental health problems can on rare occasions cause serious conditions called Serotonin Syndrome and Neuroleptic Malignant Syndrome. You must look out for certain symptoms while you are taking Seroxat, to reduce the risk of any problems. See &lsquo;<em>Conditions you need to look out for&rsquo; in <strong>Section 4</strong></em>.</p><p><strong>&nbsp;</strong></p><p><strong>Akathisia</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk46059407'><b><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'> DOCVARIABLE
vault_nd_ddef5952-7d8c-4341-85af-2c76a34db2ec \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-end'></span><![endif]--></p><p>Medicines used to treat some mental health problems can cause a feeling of inner restlessness and the urge to move (<em>akathisia)</em>. This is a rare side effect of Seroxat, and is most likely to occur in the first few weeks of treatment.</p><p>&Uacute;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tell your doctor as soon as possible </strong>if you get these symptoms.</p><p><strong>&nbsp;</strong></p><p><strong>Sexual Dysfunction</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk46059407'><b><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'> DOCVARIABLE
vault_nd_f4ecd234-1746-448c-8358-d4a28e239eda \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-end'></span><![endif]--></p><p>Medicines like Seroxat (so called SSRIs) may cause symptoms of sexual dysfunction (see Section 4). In some cases, these symptoms have continued after stopping treatment.</p><p><strong>&nbsp;</strong></p><p><strong>Bone fracture</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk46059407'><b><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'> DOCVARIABLE
vault_nd_16f14f80-36e1-488c-9e01-7d6455a40727 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-end'></span><![endif]--></p><p>There is an increased risk of bone fracture (breaking a bone) in people taking medicines like Seroxat. This risk is greatest during the early stages of treatment.</p><p>&nbsp;</p><p><strong>Alcoholic drink and Seroxat</strong><!--[if supportFields]><span style='mso-bookmark:_Hlk46059407'></span><span
style='mso-element:field-begin'></span><span style='mso-bookmark:_Hlk46059407'><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:EN-GB'> DOCVARIABLE
vault_nd_13c6cef2-ea58-4733-a907-2f06d66d2ee5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-end'></span><![endif]--></p><p>It is recommended that you don&rsquo;t drink alcohol while you&rsquo;re taking Seroxat</p><p>&nbsp;</p><p><strong>Other medicines and Seroxat</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk46059407'><b><span style='font-size:13.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:Arial;mso-bidi-font-family:
Arial;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:
EN-GB'> DOCVARIABLE vault_nd_74e5a8bd-4532-4277-b584-68216e07862e \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span></b></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-end'></span><![endif]--></p><p><strong>Tell your doctor or pharmacist if you&#39;re taking any other medicines</strong>, if you&rsquo;ve taken any recently, or if you start taking new ones. This includes herbal medicines and other medicines you bought without a prescription.</p><p>Some medicines must not be taken with Seroxat, see &lsquo;<strong>Don&rsquo;t take Seroxat</strong>&rsquo; at the beginning of <strong>Section 2</strong>.</p><p>Taking Seroxat with medicines which may raise serotonin levels in the brain, can increase your risk of side effects (see &lsquo;<em>Conditions to look out for&rsquo; </em>in <strong>Section 4</strong>). These include:</p><p>&middot;&nbsp;&nbsp;&nbsp; triptans (used to treat <strong>migraine</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp; tramadol (used to treat <strong>pain</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp; tryptophan or SSRIs (used to treat <strong>depression</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp; St. John&rsquo;s Wort (a herbal remedy used to treat <strong>depression</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp; lithium (used to treat <strong>some mental health problems</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp; fentanyl (used in <strong>anaesthesia </strong>or to treat <strong>chronic pain</strong>)</p><p>&Uacute; <strong>Tell a doctor or pharmacist </strong>if you are taking any of these. You should be closely monitored while you are taking them with Seroxat.</p><p>Some medicines can affect how Seroxat works. Seroxat can also affect how some other medicines work. These include:</p><p>&middot;&nbsp;&nbsp;&nbsp; carbamazepine, phenobarbital and phenytoin which are usually used to treat <strong>fits </strong>(seizures or epilepsy)</p><p>&middot;&nbsp;&nbsp;&nbsp; mivacurium and suxamethonium (used in <strong>anaesthesia</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp; rifampicin (used to treat <strong>tuberculosis)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; fosamprenavir and ritonavir (used to treat <strong>HIV</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp; procyclidine (used to treat <strong>Parkinson&rsquo;s disease</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp; amitriptyline, nortriptyline, imipramine and desipramine (used to treat <strong>depression</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp; perphenazine and risperidone (used to treat <strong>some mental health problems</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp; atomoxetine (used to treat <strong>attention deficit hyperactivity disorder, ADHD</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp; propafenone and flecainide (used to treat <strong>an irregular heartbeat</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp; metoprolol (used to treat <strong>high blood pressure</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp; tamoxifen (used to treat or prevent <strong>breast cancer or fertility problems</strong>)</p><p>&Uacute; <strong>Tell a doctor or pharmacist </strong>if you are taking any of these. Your doctor may decide to adjust your dose.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk46059407'><b><span style='font-size:13.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:Arial;mso-bidi-font-family:
Arial;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:
EN-GB'> DOCVARIABLE vault_nd_4e3a9e7c-6d34-4178-aa0a-a37a2a308134 \*
MERGEFORMAT <span style='mso-element:field-separator'></span></span></b></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk46059407'></span><span style='mso-element:field-end'></span><![endif]--></p><p>Seroxat is not usually recommended for use during pregnancy. If you are <strong>pregnant </strong>or <strong>think you could be, </strong>or if you are <strong>planning to become pregnant, speak to your doctor immediately</strong>. <strong>Your doctor </strong>will consider the benefit to you and the risk to your baby of taking Seroxat while you&#39;re pregnant.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some studies have reported an increase in the risk of birth defects, particularly heart defects, in babies whose mothers were taking Seroxat in the first few months of pregnancy. These studies found that about 1 in 50 babies (2%) whose mothers received Seroxat in early pregnancy had a heart defect, compared with the normal rate of 1 in 100 babies (1%) seen in the general population.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A birth complication called persistent pulmonary hypertension of the new-born (PPHN) has been seen in babies whose mothers were taking antidepressants including Seroxat during pregnancy. In PPHN, the blood pressure in the blood vessels between the baby&#39;s heart and the lungs is too high. The risk of PPHN occurring in babies whose mothers used antidepressants like Seroxat late in pregnancy was reported to be 4 to 5 times higher than the risk of PPHN seen in the general population which is about 1 to 2 cases per 1000 pregnancies.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There have been reports of premature births for mothers taking Seroxat during pregnancy. It is not known if these are due to the use of Seroxat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take Seroxat near the end of your pregnancy there may be an increased risk of excessive vaginal bleeding shortly after birth, especially if you have a history of bleeding disorders. Your doctor or midwife should be aware that you are taking Seroxat so they can advise you.</p><p>&nbsp;</p><p>If Seroxat is used until delivery, the following symptoms have been reported in babies immediately or within the first 24 hours after birth. Again, it is not known if these symptoms are due to the use of Seroxat. The symptoms are:</p><p>&middot;&nbsp;&nbsp;&nbsp; trouble with breathing</p><p>&middot;&nbsp;&nbsp;&nbsp; a blue-ish skin or being too hot or cold</p><p>&middot;&nbsp;&nbsp;&nbsp; vomiting or not feeding properly</p><p>&middot;&nbsp;&nbsp;&nbsp; being very tired, not able to sleep or constant crying</p><p>&middot;&nbsp;&nbsp;&nbsp; stiff or floppy muscles</p><p>&middot;&nbsp;&nbsp;&nbsp; tremors, jitters or fits</p><p>&Uacute; If your baby has any of these symptoms when it is born, or you are concerned about your baby&rsquo;s health, <strong>contact your doctor or midwife for advice.</strong></p><p><strong>&nbsp;</strong></p><p>The ingredients in Seroxat can pass into breast milk. <strong>If you are breast-feeding, you must check with your doctor </strong>before you take Seroxat.</p><p>&nbsp;</p><p>Medicines like Seroxat may affect your sperm. Fertility may be reduced in some men during treatment with Seroxat.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong><!--[if supportFields]><b><span style='font-size:13.0pt;
line-height:150%;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_ab881698-63a8-4c0c-aebf-9644cdab0391 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;line-height:150%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;mso-bidi-font-family:Arial;mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Seroxat can make you feel dizzy or confused and can affect your eyesight.</p><p>&Uacute; <strong>Don&rsquo;t drive or use machines </strong>if you get side effects such as these.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take Seroxat exactly as your doctor has told you to. </strong>Check with your doctor or pharmacist if you&#39;re not sure.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p><strong>The starting dose </strong>of Seroxat depends on your illness. It is usually 10 mg or 20 mg once a day. Your doctor may gradually increase your dose to help control your symptoms, up to a maximum of 50 mg or 60 mg once a day.</p><p>If you are over 65, or have liver or kidney problems, the maximum dose may be reduced.</p><p>&nbsp;</p><p><strong>How to take</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_ffc1a301-8e30-4322-bd2b-c7b433c7fef8 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Swallow the tablet with some water. Don&rsquo;t chew the tablet.</p><p>Take Seroxat in the morning with food.</p><p>Sometimes you may need to break the tablets in half to ensure you take the correct dose.</p><p>Pregnant caregivers should avoid exposure to Seroxat tablets.</p><p>&nbsp;</p><p>&Uacute; <strong>If you are not sure what to do</strong>, ask your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>How long to take it for</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_7970e8b8-ac98-4f59-9beb-b9091df153ec \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>The duration of treatment will depend on your illness. Whilst people usually feel some improvement within two weeks or so, it can take longer for the medicine to have its full effect.</p><p>Even after you start to feel better, it is important to keep taking Seroxat for as long as your doctor recommends to help prevent symptoms from returning. This can be several months after recovery from depression and may even be longer for panic disorder or obsessions and compulsions.</p><p>&nbsp;</p><p><strong>If you forget to take Seroxat</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_7c585338-18a0-4db1-89d8-7f7a119711f5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>Don&#39;t take an extra dose </strong>to make up for a missed one. Just take your next dose at the usual time.</p><p>&Uacute; <strong>If you are not sure what to do, </strong>ask your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>If you take too much Seroxat</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_a183b200-a231-4263-8059-fdf088a93421 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you take too much Seroxat you are more likely to get side effects (see <strong>Section 4</strong>). Taking too much Seroxat may also cause blood pressure changes, uncontrollable muscle contractions, anxiety, a high temperature, and a fast heartbeat.</p><p>&Uacute; If you take too much Seroxat, <strong>contact your doctor or pharmacist for advice. </strong>If possible, show them the Seroxat pack.</p><p>&nbsp;</p><p><strong>Don&rsquo;t stop Seroxat without advice</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_85bb8788-c327-4b9b-ac3a-833f374a0672 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>Don&rsquo;t stop taking Seroxat without talking to your doctor first. </strong>Your dose needs to be reduced gradually, otherwise you may get side effects (see <em>&lsquo;Symptoms seen when Seroxat is stopped&rsquo; </em>at the end of <strong>Section 4</strong>).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Seroxat can cause side effects, but not everybody gets them.</p><p>&nbsp;</p><p><strong>Conditions to look out for</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;line-height:115%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_d6d86ace-c582-4c5a-9572-8f27b96aa778 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;line-height:115%;font-family:"Times New Roman",serif;
mso-fareast-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>Severe allergic reactions</strong>. These are very rare in people taking Seroxat.</p><p>&nbsp;Signs include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; raised and itchy rash (hives)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; swelling, sometimes of the face or mouth (angioedema), causing difficulty in breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; collapse or loss of consciousness</p><p>&Uacute; <strong>Contact a doctor immediately</strong> if you get these symptoms. <strong>Stop taking Seroxat.</strong></p><p>&nbsp;</p><p><strong>Serotonin Syndrome and Neuroleptic Malignant syndrome</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span></span></b><b><span
lang=FR style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:FR;mso-fareast-language:EN-GB;mso-bidi-language:
EN-GB'> DOCVARIABLE vault_nd_0e94fbe5-2ec5-47b0-8ca7-dc07381fa66d \*
MERGEFORMAT </span></b><b><span style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Medicines that may increase serotonin activity in the brain can cause a condition called Serotonin Syndrome. This is a very rare side effect of Seroxat. Taking Seroxat with other medicines which may also raise serotonin activity in the brain, can increase the risk of this serious side effect (see &lsquo;<em>Other medicines and Seroxat&rsquo; </em>in <strong>Section 2</strong><em>). </em>Another condition called Neuroleptic Malignant Syndrome is a rare side effect of medicines used to treat mental health problems.</p><p>The symptoms of both Serotonin Syndrome and Neuroleptic Malignant Syndrome are similar. Usually more than one of the following symptoms will occur:</p><p>&middot;&nbsp;&nbsp;&nbsp; tremor</p><p>&middot;&nbsp;&nbsp;&nbsp; sudden uncontrollable jerky movements</p><p>&middot;&nbsp;&nbsp;&nbsp; muscle stiffness</p><p>&middot;&nbsp;&nbsp;&nbsp; difficulty sitting still</p><p>&middot;&nbsp;&nbsp;&nbsp; feeling very agitated or irritable</p><p>&middot;&nbsp;&nbsp;&nbsp; feeling hot or sweaty</p><p>&middot;&nbsp;&nbsp;&nbsp; increase in heart rate</p><p>The severity can increase, leading to loss of consciousness.</p><p>&egrave;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Contact your doctor urgently </strong>if you get these symptoms<strong>.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Akathisia</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_4b5b9a4b-f371-4539-b0f6-755fa49599a5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Medicines used to treat some mental health problems can cause a feeling of inner restlessness and the urge to move (<em>akathisia)</em>. This is a rare side effect of Seroxat, and is most likely to occur in the first few weeks of treatment.</p><p>&Uacute; <strong>Tell your doctor as soon as possible </strong>if you get these symptoms.</p><p><strong>&nbsp;</strong></p><p><strong>Very common side effects</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_f26088c7-eaf7-4890-8b48-bdc49b6cca83 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>These may affect <strong>more than 1 in 10 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a change in sex drive or sexual function</p><p><strong>Common side effects</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_e5f5f5f4-60aa-4fa0-addd-64086b8ed573 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>These may affect <strong>up to 1 in 10 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in sleeping (insomnia) or feeling drowsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling agitated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremors</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yawning</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick (vomiting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal dreams (including nightmares)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight gain</p><p>&nbsp;</p><p><strong>Common side effects that may show up in blood tests:</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_1acffda8-4efb-4525-877e-2800c81a9b61 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in cholesterol</p><p><strong>Uncommon side effects</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_95956d87-3865-406d-b0b3-3a1b8c2c9af3 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>These may affect <strong>up to 1 in 100 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bruising or unusual bleeding mainly of the skin and moist areas such as the mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling confused</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seeing or hearing things that are not really there (<em>hallucinations</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; involuntary muscle movements of the face, twisting movements of the body, arms and legs, tremor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dilated pupils</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a faster than normal heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure (may cause dizziness, light-headedness or fainting when standing up from a sitting or lying position)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rashes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unable to pass urine (<em>urinary retention</em>) or loss of control of the bladder (<em>urinary incontinence</em>)</p><p>&nbsp;</p><p><strong>Rare side effects</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_bc69b2b4-5f38-4741-829b-af587f1b1ed9 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>These may affect <strong>up to 1 in 1,000 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a feeling of restlessness and difficulty sitting or standing still (<em>akathisia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; episodes of hyperactivity, elation and irritability (<em>mania</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits (<em>seizures</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irresistible urge to move the legs (<em>Restless Legs Syndrome</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal secretion of breast milk in men and women</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; menstrual period disorders (including heavy periods, bleeding between periods and absence of periods)</p><p>&nbsp;</p><p><strong>Rare side effects that may show up in blood tests:</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_d917c666-0b6b-4f83-8d09-ecc2dca54542 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in sodium levels in the blood (especially in the elderly)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in substances (<em>enzymes</em>) from the liver</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in a hormone called prolactin</p><p><strong>Very rare side effects</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_fcc8620d-6c1c-40a7-ac40-a8d206a513fd \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>These may affect <strong>up to 1 in 10,000 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serotonin Syndrome</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, which may blister, and looks like small targets (central dark spots surround by a paler area, with a dark ring around the edge) called <em>erythema multiforme</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (<em>Stevens-Johnson syndrome</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a widespread rash with blisters and skin peeling on much of the body surface (<em>toxic epidermal necrolysis</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased amounts of a hormone (ADH) that causes water retention</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glaucoma (a condition caused by raised pressure in the eye)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in the digestive system (passing blood in the stools or black stools)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver (<em>hepatitis</em>), sometimes causing yellowing of the skin and the whites of the eyes (<em>jaundice)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sensitivity of the skin to sunlight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of hands, ankles or feet</p><p><strong>Very rare side effects that may show up in blood tests:</strong><!--[if supportFields]><b><span style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_d8cef1c9-5d4b-4c1b-9e28-373eb5c83b95 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in number of blood platelets (cells that help blood to clot)</p><p>&nbsp;</p><p><strong>If you get side effects</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_c0198091-83ac-48de-80ca-22236e47afe2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>&Uacute; <strong>Tell your doctor or pharmacist </strong>if any of the side effects listed becomes <strong>severe or troublesome</strong>, or if you notice any side effects not listed in this leaflet.</p><p>&nbsp;</p><p><strong>Symptoms seen when Seroxat is stopped</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_87e27c8f-dfe7-457d-91a9-6ffc805e38a5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Stopping medicines used for treating mental health problems often causes unwanted symptoms. The symptoms are more likely to occur in the first few days of stopping treatment and usually go away within a few weeks.</p><p>If you need to stop taking Seroxat, your doctor may reduce your dose gradually. This should help to reduce any effects and their severity.</p><p><strong>Common symptoms seen when Seroxat is stopped:</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_acf61e62-f25d-4d2b-a751-13a4ea4b2377 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>These may affect <strong>up to 1 in 10 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feelings like pins and needles, electric shock sensations and persistent noise in the ears (<em>tinnitus</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleep disturbances including intense dreams</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling anxious</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&nbsp;</p><p><strong>Uncommon symptoms seen when Seroxat is stopped:</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_48c89f79-a620-45dd-8444-324be8f3af45 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>These may affect <strong>up to 1 in 100 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling restless or agitated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremors</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling confused</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&Uacute; <strong>Talk to your doctor </strong>if these symptoms become <strong>severe or troublesome</strong>.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Keep out of the reach and sight of children.</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_b7ec044e-fc2f-4600-8afe-db041931d06b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use SEROXAT after the expiry date which is stated on the pack after &lsquo;Exp&rsquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store SEROXAT below 30&deg;C. Store it in its original packaging in dry place.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor tells you to stop taking SEROXAT, it is important to return any remnants which are left over to your pharmacist.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have any unwanted SEROXAT tablets, don&rsquo;t dispose of them in your wastewater or household rubbish. Ask your pharmacist how to dispose of medicines no longer required. This will help to protect the environment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transport and store medicine in the original container or blister.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What SEROXAT contains</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_4680c3a9-d096-42a6-ae5b-218260c8a98d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:13.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
Arial;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>The active substance is paroxetine as paroxetine hydrochloride hemihydrate. SEROXAT tablets come in different strengths.</p><p>Each tablet contains:</p><p>20 mg paroxetine.</p><p>The other ingredients are:</p><p>Tablet cores: Calcium phosphate (E341), hydroxypropyl methylcellulose (E464), sodium starch glycollate, magnesium stearate (E572).</p><p>Film-coat: hydroxypropyl methylcellulose (E464), titanium dioxide (E171), polyethylene glycol, and&nbsp; polysorbate 80 (E433).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                20 mg tablets: White, film-coated, oval shaped, biconvex tablets.
Tablets either in Foil blister packs, child-resistant foil blister packs or polypropylene bottles.

Not All packs are marketed in every country.
SEROXAT is a trademark owned by or licensed to GSK group of companies.
© 2024 GSK group of companies., all rights reserved.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by:</strong></p><p>Delpharm Poznań Sp&oacute;łka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznan, Poland</p><p>&nbsp;</p><p><strong>Packed by:</strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, Kingdom of Saudi Arabia</p><p>&nbsp;</p><p><strong>Marketing Authorisation Holder</strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, Kingdom of Saudi Arabia</p><p>&nbsp;</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; Kingdom of Saudi Arabia.</p><p><em>*member of the GlaxoSmithKline group of companies.</em></p><p>&nbsp;</p><p><strong>For any information about this medicinal product, please contact:</strong><!--[if supportFields]><b><span style='font-size:
12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_997ef79c-c8ea-4d4a-aaaa-d68c4e816434 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>GlaxoSmithKline - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel: +966 -12- 6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966 -56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: gcc.medinfo@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:roundrect
 id="Rectangle_x003a__x0020_Rounded_x0020_Corners_x0020_6" o:spid="_x0000_s1026"
 style='position:absolute;margin-left:0;margin-top:8.75pt;width:475.2pt;
 height:223.5pt;z-index:251664384;visibility:visible;mso-wrap-style:square;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:left;mso-position-horizontal-relative:margin;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-height-percent:0;mso-height-relative:margin;v-text-anchor:middle'
 arcsize="10923f" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokecolor="windowText" strokeweight="1.5pt">
 <w:wrap anchorx="margin"/>
</v:roundrect><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="636" height="301" src="file:///C:/Users/aa630244/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong>&nbsp;</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>- National Pharmacovigilance centre (NPC)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting hotline: 19999</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail : npc.drug@sfda.gov.sa&nbsp;&nbsp;&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p><strong>- GlaxoSmithKline - Head Office, Jeddah</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel: +966-12-6536666</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: saudi.safety@gsk.com</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version Number: GDS48
Version Date: 08 December 2021 

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">المادة الفعالة في سيروكسات هي پاروكسيتين، التي تنتمي لمجموعة أدوية تسمى مثبطات امتصاص السيروتينين الاختيارية (SSRIs). وذلك للبالغين من سن 18 سنة فما فوق يستخدم سيروكسات في علاج:</p><ul><li dir="RTL">اضطرابات الاكتئاب الحادة</li><li dir="RTL">اضطراب الوسواس القهري</li><li dir="RTL">نوبات هلع، تشمل التي تحدث بسبب الخوف من الأماكن المفتوحة (رهاب الخلاء(</li><li dir="RTL">القلق الشامل أو القلق بسبب مواقف مثل التواصل أو الأداء الاجتماعي</li><li dir="RTL">القلق التالي لحدث صادم (الاضطراب النفسي الناشئ عن الصدمة(</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">هذه الحالات تحدث عندما تكون المادة التي تدعى سيروتينين مستوياتها منخفضة في المخ.</p><p dir="RTL">پاروكسيتين يعمل على زيادة مستويات السيروتينين في المخ.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل سيروكسات</strong></p><ul><li dir="RTL">إذا كنت مصاب <strong>بالحساسية</strong> (الحساسية المفرطة) للپاروكسيتين أو أي مواد أخرى في سيروكسات (المدرجة في فقرة 6)</li><li dir="RTL">إذا كنت تتناول أو تناولت مؤخراً (خلال الأسبوعين الأخيرين) <strong>عقاقير</strong><strong> </strong><strong>لعلاج</strong><strong> </strong><strong>الاكتئاب</strong><strong> </strong>تدعى <strong>مثبطات</strong><strong> </strong><strong>أوكسيديز</strong><strong> </strong><strong>أحادي</strong><strong> </strong><strong>الأمين</strong><strong> (</strong><strong>MAOIs</strong><strong>).</strong></li><li dir="RTL">إذا كنت تتناول أو تناولت مؤخراً (خلال الأسبوعين الأخيرين) عقار مضاد حيوي يدعى <strong>لينيزوليد</strong></li><li dir="RTL">إذا كنت تتناول أو تناولت مؤخراً (خلال الأسبوعين الأخيرين) عقار يدعى كلورايد ميثيل ثيونينيوم (<strong>ميثيلين</strong><strong> </strong><strong>أزرق</strong> (</li><li dir="RTL">إذا كنت تتناول <strong>عقاقير</strong><strong> </strong><strong>تدعى</strong><strong> </strong><strong>ثيوريدازاين</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>بيموزايد</strong> (عادة يستخدم لعلاج انفصام الشخصية (</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp; f&nbsp;&nbsp; إذا كنت تعتقد أن أيا مما سبق ينطبق عليك، <strong>لا</strong><strong> </strong><strong>تستعمل</strong><strong> </strong><strong>سيروكسات</strong><strong> </strong>حتى تتأكد من طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توخى</strong><strong> </strong><strong>الحذر</strong><strong> </strong><strong>الشديد</strong><strong> </strong><strong>عند</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>سيروكسات</strong></p><p dir="RTL"><strong>لايوصى</strong><strong> </strong><strong>باستعمال</strong><strong> </strong><strong>سيروكسات</strong><strong> </strong><strong>للأشخاص</strong><strong> </strong><strong>في</strong><strong> </strong><strong>سن</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> 18 </strong><strong>سنة</strong><strong>. </strong>فعالية سيروكسات لم تحدد في هذه الفئة العمرية.</p><p dir="RTL">الأدوية التي تستخدم لعلاج الاكتئاب ومشاكل الصحة العقلية قد تزيد من خطر الأفكار الانتحارية والسلوك الانتحاري في الأطفال والمراهقين في سن أقل من 18 سنة. لاتوجد معلومات على المدى الطويل عن مأمونية سيروكسات في هذه الفئة العمرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قبل</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>تبدأ</strong><strong> </strong><strong>بتناول</strong><strong> </strong><strong>سيروكسات</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>يحتاج</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>يعرف</strong><strong>:</strong></p><ul><li dir="RTL">إذا كنت تتناول <strong>عقاقير</strong><strong> </strong><strong>لعلاج</strong><strong> </strong><strong>الاكتئاب</strong><strong> </strong><strong>تدعى</strong><strong> </strong><strong>مثبطات</strong><strong> </strong><strong>أوكسيديز</strong><strong> </strong><strong>أحادي</strong><strong> </strong><strong>الأمين</strong><strong> (</strong><strong>MAOIs</strong><strong>)</strong><strong> </strong>وتاريخ توقفك عن تناولها</li><li dir="RTL">إذا كنت تتناول مضاد حيوي يسمى <strong>لينيزوليد</strong><strong> </strong>وتاريخ توقفك عن تناوله</li><li dir="RTL">إذا كنتي تتناولين <strong>تامكسيفين</strong> (يستخدم لعلاج والوقاية من سرطان الثدي (</li><li dir="RTL">إذا سبق وأن أصبت <strong>بنوبات</strong><strong> </strong><strong>فرط</strong><strong> </strong><strong>النشاط</strong>، <strong>انتشاء</strong><strong> </strong><strong>واضطراب</strong><strong> </strong>(هوس)</li><li dir="RTL">إذا سبق وأن أصبت <strong>بفترات</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الهوس</strong><strong> </strong><strong>تتبادل</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>فترات</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الاكتئاب</strong><strong> </strong>(اضطراب المزاج ثنائي القطب (</li><li dir="RTL">إذا كان لديك <strong>مرض</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الكلى</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الكبد</strong></li><li dir="RTL">إذا كان لديك <strong>مرض</strong><strong> </strong><strong>في</strong><strong> </strong><strong>القلب</strong></li><li dir="RTL">إذا كان <strong>رسم القلب (مخطط كهربية القلب/ </strong><strong>ECG</strong><strong>)</strong><strong> </strong><strong>به خلل يُعرف باسم الفاصل الزمني المطول</strong><strong>(prolonged QT interval)</strong><strong> </strong>، أو إذا كنت تتناول أدوية قد تؤثر على الفاصل الزمني في مخطط كهربية القلب.</li><li dir="RTL">إذا كنت مصاب <strong>بالصرع</strong></li><li dir="RTL">إذا كنت مصاب <strong>بالماء</strong><strong> </strong><strong>الأزرق</strong> (حالة سببها ارتفاع ضغط دم العين(</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ في <strong>مشاكل</strong><strong> </strong><strong>النزيف</strong>، أو كنت تتناول أدوية تزيد من مخاطر النزيف</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;f&nbsp;&nbsp; &nbsp;<strong>تأكد</strong><strong> </strong><strong>من</strong><strong> </strong><strong>طبيبك</strong><strong> </strong>إذا كنت تعتقد أن أيا مما سبق ينطبق عليك. طبيبك سيقرر إذا ما كان سيروكسات مناسبا لك، أو إذا كنت تحتاج لفحوصات إضافية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أفكار</strong><strong> </strong><strong>انتحارية</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>تدهور</strong><strong> </strong><strong>حالتك</strong></p><p dir="RTL">إذا كنت مصابا بالاكتئاب، قد يكون لديك في بعض الأحيان أفكار انتحارية أو أفكار لإيذاء نفسك. أدوية مثل سيروكسات تتطلب وقتاً لكي تعمل (عادة أسبوعين لكن في بعض الأحيان أكثر)، الأفكار الإنتحارية أو أفكار إيذاء نفسك قد تستمر أو تزيد، خصوصا عندما تبدأ باستخدام سيروكسات</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يزداد تفكيرك بهذه الأشياء إذا كنت:</p><ul><li dir="RTL">إذا كنت شاباً صغيراً</li><li dir="RTL">سبق وأن كان لديك أفكار من هذا النوع</li><li dir="RTL">قمت بتغيير الجرعة مؤخراً</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أفكار محزنة أو سبق وأن كان لديك هذه الأفكار، أو إذا لاحظت أنك تشعر بأنك أسوأ أو إذا تطورت لديك أعراض جديدة أثناء استعمالك لسيروكسات:</p><p dir="RTL">f&nbsp; <strong>اتصل</strong><strong> </strong><strong>بطبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>اذهب</strong><strong> </strong><strong>الى</strong><strong> </strong><strong>المستشفى</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الفور</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>قد</strong><strong> </strong><strong>تجد</strong><strong> </strong><strong>أنه</strong><strong> </strong><strong>من</strong><strong> </strong><strong>المفيد</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>تخبر</strong><strong> </strong><strong>قريب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>صديق</strong><strong> </strong><strong>مقرب</strong> بأنك تعاني من الاكتئاب، واطلب منهم أن يقرأوا هذه النشرة. تستطيع أن تسألهم إذا كانوا يعتقدون أن اكتئابك أصبح أسوأ، أو إذا كانوا قلقين حول التغيرات في سلوكك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حالات</strong><strong> </strong><strong>تحتاج</strong><strong> </strong><strong>لأخذ</strong><strong> </strong><strong>الحذر</strong><strong> </strong><strong>فيها</strong><strong>:</strong></p><p dir="RTL">عقاقير مثل سيروكسات تستخدم لعلاج حالات الاضطرابات العقلية تستطيع في مناسبات نادرة أن تسبب حالات خطيرة تسمى متلازمة سيروتينين والمتلازمة الخبيثة للعقار المضاد للذهان. عليك الحذر من بعض الأعراض المعينة أثناء استعمالك لسيروكسات، للتقليل من خطر حدوث أي مشاكل. انظر &quot;حالات يجب الحذر منها&quot; <strong>في</strong><strong> </strong><strong>الفقرة</strong><strong> 4</strong> .</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التململ</strong></p><p dir="RTL">العقاقير التي تستخدم لعلاج بعض المشاكل العقلية قد تسبب شعور داخلي بعدم الراحة والحاجة الشديدة للحركة (التململ). هذا عرض جانبي نادر الحدوث مع سيروكسات، وغالبا ما يحدث في الأسابيع الأولى القليلة من العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">f&nbsp; <strong>أخبر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>بأقرب</strong><strong> </strong><strong>فرصة</strong><strong> </strong>إذا كان لديك أي من هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اختلال الوظيفة الجنسية</strong><!--[if supportFields]><b><span
lang=AR-EG style='font-size:14.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:AR-EG'><span style='mso-element:field-begin'></span> </span></b><b><span
dir=LTR style='font-size:14.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:AR-EG'>DOCVARIABLE</span></b><span dir=RTL></span><span
dir=RTL></span><b><span style='font-size:14.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:AR-EG'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span
dir=LTR style='font-size:14.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:AR-EG'>VAULT_ND_81a76d96-2d6c-4355-b5d1-d3ea02fe70a1 \*
MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-size:14.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-language:AR-EG'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-EG><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-EG style='font-size:14.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:AR-EG'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">قد تتسبب عقاقير مثل سيروكسات (ما يسمى بمثبطات امتصاص السيروتينين الاختيارية) في أعراض اختلال الوظيفة الجنسية (انظر الفقرة 4). وفي بعض الحالات، استمرت هذه الأعراض بعد التوقف عن العلاج.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحطم</strong><strong> </strong><strong>العظام</strong></p><p dir="RTL">هناك خطر متزايد لتحطم العظام (كسر في العظم) في الأشخاص الذين يتناولون عقاقير مثل سيروكسات، يكون الخطر أكبر في المراحل المبكرة من العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شرب</strong><strong> </strong><strong>الكحول</strong><strong> </strong><strong>وسيروكسات</strong></p><p dir="RTL">ينصح بعدم شرب الكحول خلال فترة استعمالك للسيروكسات</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية</strong><strong> </strong><strong>الأخرى</strong><strong> </strong><strong>وسيروكسات</strong></p><p dir="RTL"><strong>أخبر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>تستعمل</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>أدوية</strong><strong> </strong><strong>أخرى</strong><strong>. </strong>إذا استعملت أي عقاقير مؤخراً ، أو إذا بدأت باستعمال عقاقير جديدة. هذا يشمل العقاقير العشبية والعقاقير الأخرى التي تشتريها بدون وصفة طبية .</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ألا تؤخذ بعض العقاقير مع سيروكسات، انظر<strong> &rsquo;</strong><strong>لا تستعمل سيروكسات</strong><strong>&lsquo; </strong>في بداية<strong> </strong><strong>الفقرة</strong><strong> 2</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">استعمال سيروكسات قد يرفع مستويات السيروتنين في المخ، يزيد من خطر حدوث الأعراض الجانبية (انظر&rsquo;<em>حالات</em><em> </em><em>يجب</em><em> </em><em>الحذر</em><em> </em><em>منها</em>&lsquo; في <strong>الفقرة</strong><strong> 4</strong> ). هذه تشمل:</p><ul><li dir="RTL">تربتانات (تستخدم في علاج <strong>الشقيقة</strong>(</li><li dir="RTL">ترامادول (يستخدم في علاج <strong>الألم</strong>(</li><li dir="RTL">تريبتوفان أو SSRIs(يستخدم في علاج<strong> </strong><strong>الاكتئاب</strong>(</li><li dir="RTL">عشبة القديس جون (عقار عشبي يستخدم لعلاج <strong>الاكتئاب</strong>(</li><li dir="RTL">ليثيوم (يستخدم لعلاج <strong>بعض</strong><strong> </strong><strong>الاضطرابات</strong><strong> </strong><strong>العقلية</strong><strong>(</strong></li><li dir="RTL">فنتانيل ( يستخدم <strong>في</strong><strong> </strong><strong>التخدير</strong><strong> </strong>أو لعلاج<strong> </strong><strong>الألم</strong><strong> </strong><strong>المزمن</strong><strong>(</strong></li></ul><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;<strong>f</strong><strong>&nbsp; </strong><strong>أخبر</strong><strong> </strong><strong>الطبيب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong> إذا كنت تستعمل أياً من هذه. يجب أن تكون تحت المراقبة عن كثب أثناء استعمالك لسيروكسات</p><p dir="RTL">بعض العقاقير قد تؤثر على كيفية عمل سيروكسات، أيضا قد يؤثر سيروكسات على كيفية عمل العقاقير الأخرى. هذه تشمل:</p><ul><li dir="RTL">كاربامازيبين، فينوباربيتال وفينيتوين الذين يستخدمون في العادة لعلاج <strong>النوبات</strong> (الخلجان أو الصرع(</li><li dir="RTL">مياڤكوريم وسوكساميثونيوم (يستخدمان في <strong>التخدير</strong>(</li><li dir="RTL">ريفامبيسين (يستخدم في علاج <strong>السل</strong>(</li><li dir="RTL">فوسامبريناڤير وريتوناڤير (يستخدم في علاج ا<strong>لإيدز</strong>(</li><li dir="RTL">بروسيكلايدين (يستخدم في علاج <strong>مرض</strong><strong> </strong><strong>باركنسون</strong>(</li><li dir="RTL">أميتريبتيلين، نورتريبتيلين، إيميبرامين وديسيبرامين (يستخدم في علاج <strong>الإكتئاب</strong>(</li><li dir="RTL">بيرفينازين وريسبيريدون (يستخدم في علاج <strong>بعض</strong><strong> </strong><strong>المشاكل</strong><strong> </strong><strong>العقلية</strong>(</li><li dir="RTL">أتوموكسيتين (يستخدم في علاج <strong>نقص</strong><strong> </strong><strong>الانتباه</strong><strong> </strong><strong>المصاحب</strong><strong> </strong><strong>لاضطراب</strong><strong> </strong><strong>فرط</strong><strong> </strong><strong>الحركة،</strong><strong> </strong><strong>ADHD</strong>)</li><li dir="RTL">بروبافينون وفليكاينيد (يستخدم في علاج <strong>عدم</strong><strong> </strong><strong>انتظام</strong><strong> </strong><strong>ضربات</strong><strong> </strong><strong>القلب</strong>(</li><li dir="RTL">ميتوبرولول (يستخدم في علاج <strong>ضغط</strong><strong> </strong><strong>الدم</strong><strong> </strong><strong>المرتفع</strong>(</li><li dir="RTL">تاموكسيفين (يستخدم في علاج <strong>سرطان</strong><strong> </strong><strong>الثدي</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>مشاكل</strong><strong> </strong><strong>الخصوبة</strong>(</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp; f &nbsp;&nbsp;&nbsp;<strong>أخبر</strong><strong> </strong><strong>الطبيب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong> إذا كنت تستعمل أيا منها. قد يقرر طبيبك تعديل جرعتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong><strong> </strong><strong>الطبيعية</strong></p><p dir="RTL">لا ينصح باستعمال سيروكسات أثناء الحمل. إذا كنت <strong>حامل،</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>تعتقدين</strong><strong> </strong><strong>أنك</strong><strong> </strong><strong>حامل،</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>تخططين</strong><strong> </strong><strong>للحمل،</strong><strong> </strong><strong>تحدثي</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الفور</strong><strong>.</strong><strong>&nbsp; </strong><strong>طبيبك</strong> سوف يقيم المنافع والمضار لطفلك عند استعمالك سيروكسات أثناء الحمل.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الدراسات تشير إلى زيادة مخاطر حدوث تشوهات الولادة، خصوصاً خلل في القلب، في الأطفال الذين كانت أمهاتهم يستعملن سيروكسات في الأشهر القليلة الأولى من الحمل. هذه الدراسات وجدت أن حوالي طفل واحد من 50 طفل ( 2٪ ) من الذين كانت أمهاتهم يستعملن سيروكسات في المرحلة المبكرة من الحمل أصيبوا بخلل في القلب، بالمقارنة مع المعدل الطبيعي طفل واحد من كل 100 ( 1٪ ) في المجتمع بشكل عام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعقيدات الولادة التي تسمى ارتفاع الضغط الرئوي المتواصل للأطفال حديثي الولادة (PPHN) &nbsp;لوحظت في الأطفال الذين كانت أمهاتهم يستعملن عقاقير مضادة للاكتئاب بما فيها سيروكسات أثناء الحمل. في حالة PPHN ، يكون ضغط الدم مرتفعاً جداً &nbsp;في الأوعية الدموية بين قلب الطفل ورئته. تم تسجيل تضاعف خطر الإصابة PPHN في الأطفال الذين كانت أمهاتهم يستعملن عقاقير مضادة للاكتئاب مثل سيروكسات في المرحلة المتأخرة للحمل من 4 إلى 5 مرات أكثر من حدوثه في المجتمع بشكل عام والذي يكون معدل الإصابة به 1 إلى 2 حالة لكل 1000 حالة حمل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم تسجيل حالات لولادات مبكرة لأمهات يستعملن سيروكسات أثناء الحمل. من غير المعلوم إذا كان هذا له صلة باستخدام سيروكسات أثناء الحمل.</p><ul><li dir="RTL">إذا تناولتِ سيروكسات قرب نهاية الحمل قد يكون هناك خطر متزايد من حدوث نزيف مهبلي مفرط بعد الولادة بقليل، خاصةً إذا كان لديك تاريخ من الاضطرابات النزفية. يجب أن يكون طبيبكِ أو قابلتكِ على دراية أنكِ تتناولين سيروكسات حتى يتمكنوا من تقديم النصيحة لكِ.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تم استعمال سيروكسات حتى الولادة، الأعراض التالية سجلت في الأطفال على الفور أو بعد 24 ساعة من الولادة. مجددا ، من غير المعروف ما إذا كانت هذه الأعراض بسبب استخدام سيروكسات أم لا. الأعراض هي:</p><ul><li dir="RTL">صعوبة في التنفس</li><li dir="RTL">زرقة الجلد أو برودة أو سخونة شديدة</li><li dir="RTL">التقيؤ أو عدم الرضاعة بشكل صحيح</li><li dir="RTL">التعب الشديد، عدم القدرة على النوم أو بكاء مستمر</li><li dir="RTL">تصلب أو ليونة العضلات</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رعاش، هياج أو نوبات</p><p dir="RTL">f &nbsp;&nbsp;إذا كان طفلك لديه أي من هذه الأعراض عند الولادة، أوكنت قلقة حول صحة طفلك، <strong>إتصلي</strong><strong> </strong><strong>بطبيبك</strong><strong> </strong><strong>أوالقابلة</strong><strong> </strong><strong>للنصيحة</strong><strong>.</strong></p><p dir="RTL">مكونات سيروكسات تستطيع أن تمُر إلى حليب الثدي<strong>. </strong><strong>إذا</strong><strong> </strong><strong>كنتِ</strong><strong> </strong><strong>تقومين</strong><strong> </strong><strong>بالرضاعة</strong><strong> </strong><strong>الطبيعية،</strong><strong> </strong><strong>يجب</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>تراجعي</strong><strong> </strong><strong>طبيبك</strong> قبل استعمال سيروكسات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عقاقير مثل سيروكسات قد تؤثر على الحيوانات المنوية لديك. الخصوبة قد تقل في بعض الرجال أثناء العلاج بسيروكسات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">سيروكسات قد يجعلك تشعر بدوار أو ارتباك ويؤثر على رؤيتك.</p><p dir="RTL">f &nbsp;&nbsp;<strong>&nbsp;</strong><strong>لا</strong><strong> </strong><strong>تقوم</strong><strong> </strong><strong>بالقيادة</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>الآلات</strong> إذا حدث لك مثل هذه الأعراض الجانبية .</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>دائما</strong><strong> </strong><strong>استعمل</strong><strong> </strong><strong>سيروكسات</strong><strong> </strong><strong>كما</strong><strong> </strong><strong>أخبرك</strong><strong> </strong><strong>الطبيب</strong><strong>. </strong>تأكد من طبيبك او الصيدلي إذا كنت لست متأكدا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ماهي</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>سيروكسات</strong><strong> </strong><strong>التي</strong><strong> </strong><strong>يجب</strong><strong> </strong><strong>تناولها</strong></p><p dir="RTL"><strong>الجرعة</strong><strong> </strong><strong>الأولية</strong> من سيروكسات تعتمد على مرضك. هي عادة 10 ملجم أو 20 ملجم مرة واحدة يوميا. قد يزيد طبيبك الجرعة الخاصة بك تدريجيا للتحكم في الأعراض، حتى الوصول للجرعة القصوى وهي 50 ملجم إلى 60 ملجم مرة واحدة يوميا .</p><p dir="RTL">إذا كان سنك أكبر من 65 عاما أو لديك مشاكل في الكبد أو الكلى، الجرعة القصوى قد يتم تخفيضها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية</strong><strong> </strong><strong>الاستعمال</strong></p><p dir="RTL">ابتلع القرص كاملا مع بعض الماء. لا تمضغ القرص.</p><p dir="RTL">استعمل سيروكسات في الصباح مع الطعام.</p><p dir="RTL">في بعض الأحيان قد تحتاج إلى كسر القرص الى نصفين للتأكد من أنك تأخذ الجرعة الصحيحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;f &nbsp;<strong>&nbsp;</strong><strong>إذا</strong><strong> </strong><strong>لم</strong><strong> </strong><strong>تكن</strong><strong> </strong><strong>متأكدا</strong><strong> </strong><strong>مما</strong><strong> </strong><strong>ستفعل</strong>، اسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ماهي</strong><strong> </strong><strong>المدة</strong><strong> </strong><strong>اللازمة</strong><strong> </strong><strong>للاستعمال</strong></p><p dir="RTL">مدة العلاج تعتمد على حالتك المرضية. بينما اللأشخاص يشعرون ببعض التحسن خلال أسبوعين، قد يستغرق الدواء وقتاً أطول ليصل إلى الفعالية الكاملة.</p><p dir="RTL">حتى لو بدأت تشعر بأنك أفضل، من المهم أن تستخدم سيروكسات كما أوصاك طبيبك لمنع الأعراض من العودة. هذا قد يستغرق عدة أشهر بعد التعافي من الاكتئاب وقد يستغرق وقتا أطول لحالات الهلع أو اضطراب الوسواس القهري.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>سيروكسات</strong></p><p dir="RTL"><strong>لا</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>إضافية</strong> لتعوض الجرعة المنسية. فقط تناول جرعتك القادمة في وقتها المعتاد.</p><p dir="RTL">f&nbsp; <strong>إذا</strong><strong> </strong><strong>لم</strong><strong> </strong><strong>تكن</strong><strong> </strong><strong>متأكدا</strong><strong> </strong><strong>مما</strong><strong> </strong><strong>ستفعل</strong>، اسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>تناولت</strong><strong> </strong><strong>سيروكسات</strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>من</strong><strong> </strong><strong>اللازم</strong></p><p dir="RTL">إذا تناولت سيروكسات أكثر من اللازم ستكون معرض أكثر للإصابة بالأعراض الجانبية (<strong>انظر</strong><strong> </strong><strong>الفقرة </strong><strong>4</strong> ). تناول سيروكسات أكثر من اللازم قد يسبب أيضا تغيرات في ضغط الدم، إنقباضات عضلية لاإرادية، قلق، إرتفاع في درجة الحرارة، وضربات قلب سريعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">f&nbsp; إذا تناولت سيروكسات أكثر من اللازم، <strong>اتصل</strong><strong> </strong><strong>بطبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong> </strong><strong>للنصيحة</strong>.&nbsp; إذا كان بالإمكان، أظهر لهم عبوة سيروكسات.</p><p dir="RTL"><strong>لا</strong><strong> </strong><strong>توقف</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>سيروكسات</strong><strong> </strong><strong>بدون</strong><strong> </strong><strong>نصيحة</strong></p><p dir="RTL"><strong>لا</strong><strong> </strong><strong>توقف</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>سيروكسات</strong><strong> </strong><strong>قبل</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>تتحدث</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أولا</strong> . جرعتك تحتاج لأن تقل تدريجياً، عدا ذلك قد تصاب</p><p dir="RTL">بأعراض جانبية (انظر &rsquo;أعراض تشاهد عند إيقاف سيروكسات&lsquo; في نهاية <strong>الفقرة</strong><strong> 4</strong> )</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، سيروكسات قد يسبب أعراضاً جانبية، لكنها لا تصيب كل شخص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حالات</strong><strong> </strong><strong>يجب</strong><strong> </strong><strong>الحذر</strong><strong> </strong><strong>منها</strong></p><p dir="RTL"><strong>تفاعلات</strong><strong> </strong><strong>الحساسية</strong><strong> </strong><strong>الشديدة</strong><strong>. </strong>وتكون نادرة جدا في الأشخاص الذين يستعملون سيروكسات العلامات تشمل:</p><ul><li dir="RTL">طفح جلدي بارز ومصحوب بحكة) شرى (</li><li dir="RTL">انتفاخ، أحيانا في الوجه أو الفم) وذمة وعائية (، تسبب صعوبة في التنفس</li><li dir="RTL">انهيار أو فقدان للوعي</li></ul><p dir="RTL">&nbsp;f <strong>اتصل</strong><strong> </strong><strong>بطبيبك</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الفور</strong><strong> </strong>إذا أصبت بهذه الأعراض. <strong>توقف</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>سيروكسات</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>متلازمة</strong><strong> </strong><strong>سيروتينين</strong><strong> </strong><strong>والمتلازمة</strong><strong> </strong><strong>الخبيثة</strong><strong> </strong><strong>للعقار</strong><strong> </strong><strong>المضاد</strong><strong> </strong><strong>للذهان</strong></p><p dir="RTL">العقاقير التي قد تزيد من نشاط السيروتينين في المخ قد تسبب حالة تسمى متلازمة سيروتينين. هذا عرض جانبي نادر جدا مع سيروكسات استعمال سيروكسات مع عقاقير أخرى قد يرفع من نشاط السيروتيننين في المخ، قد يزيد من احتمالية حدوث أعراض جانبية خطيرة )انظر &rsquo;سيروكسات وأدوية أخرى&lsquo; في <strong>الفقرة 2</strong> .(حالة أخرى تسمى المتلازمة الخبيثة للعقار المضاد للذهان هي عرض جانبي نادر الحدوث مع العقاقير التي تستخدم في علاج مشاكل العقل الصحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض نفسها لكل من متلازمة السيروتينين والمتلازمة الخبيثة للعقار المضاد للذهان. عادة أكثر من واحد من الأعراض التالية سيحدث:</p><ul><li dir="RTL">رجفة</li><li dir="RTL">حركات لا إرادية مفاجئة متشنجة</li><li dir="RTL">تصلب في العضلات</li><li dir="RTL">صعوبة في الجلوس</li><li dir="RTL">شعور بانفعال شديد أو اضطراب</li><li dir="RTL">الإحساس بالحر أو التعرق</li><li dir="RTL">زيادة في معدل ضربات القلب</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">شدة العرض يمكن أن تزداد، مما يؤدي إلى فقدان الوعي.</p><p dir="RTL">f <strong>اتصل</strong><strong> </strong><strong>بطبيبك</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الفور</strong>، إذا كان لديك أي من هذه الأعراض</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التململ</strong></p><p dir="RTL">العقاقير التي تستخدم لعلاج مشاكل الصحة العقلية قد تسبب إحساس داخلي بعدم الراحة ورغبة ملحة في الحركة )تململ(. هذا العرض نادر الحدوث مع سيروكسات، غالبا ما يحدث في الأسابيع الأولى القليلة من العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">f <strong>أخبر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>في</strong><strong> </strong><strong>أقرب</strong><strong> </strong><strong>وقت</strong><strong> </strong><strong>ممكن</strong><strong> </strong>إذا أصبت بأي من هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>شائعة</strong><strong> </strong><strong>جدا:</strong></p><p dir="RTL">قد تصيب <strong>أكثر من</strong><strong> </strong><strong>فرد</strong><strong> </strong><strong>واحد</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10</strong> أفراد:</p><ul><li dir="RTL">شعور بالتعب )غثيان(</li><li dir="RTL">تغير في الرغبة الجنسية أو الوظيفة الجنسية</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>شائعة</strong> :</p><p dir="RTL">قد تصيب <strong>حتى</strong><strong> </strong><strong>فرد</strong><strong> </strong><strong>واحد</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10</strong> أفراد:</p><ul><li dir="RTL">نقص الشهية</li><li dir="RTL">صعوبة في النوم )أرق( أو شعور بالنعاس</li><li dir="RTL">شعور بالهياج</li><li dir="RTL">شعور بالدوار</li><li dir="RTL">ارتعاش</li><li dir="RTL">صداع</li><li dir="RTL">عدم وضوح في الروية</li><li dir="RTL">تثاؤب</li><li dir="RTL">جفاف في الفم</li><li dir="RTL">إمساك</li><li dir="RTL">إسهال</li><li dir="RTL">شعور بالمرض (قيء)</li><li dir="RTL">تعرق</li><li dir="RTL">شعور بالضعف</li><li dir="RTL">أحلام غير معتادة )تشمل الكوابيس(</li><li dir="RTL">زيادة الوزن</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>شائعة</strong><strong> </strong><strong>قد</strong><strong> </strong><strong>تظهر</strong><strong> </strong><strong>في</strong><strong> </strong><strong>اختبارات</strong><strong> </strong><strong>الدم</strong><strong>:</strong></p><ul><li dir="RTL">زيادة الكوليسترول</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية غير شائعة:</strong></p><p dir="RTL">قد تصيب <strong>حتى</strong><strong> </strong><strong>فرد</strong><strong> </strong><strong>واحد</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 100</strong> فرد:</p><ul><li dir="RTL">تكدم أو نزف غير معتاد بشكل رئيسي في الجلد والمناطق الرطبة مثل الفم</li><li dir="RTL">شعور بالارتباك</li><li dir="RTL">رؤية أو سماع أشياء غير موجودة في الواقع )هلوسة(</li><li dir="RTL">حركات عضلية لا إرادية في الوجه، حركات التوائية في الجسد، الذراعين والقدمين، ارتعاش</li><li dir="RTL">توسع الحدقة</li><li dir="RTL">ضربات قلب أسرع من المعتاد</li><li dir="RTL">انخفاض ضغط الدم )قد يسبب دوار، خفة في الرأس أو غشيان عند الوقوف من وضعية الجلوس أو الاستلقاء(</li><li dir="RTL">طفح جلدي</li><li dir="RTL">عدم القدرة على التبول )احتباس بولي( أو فقدان التحكم في المثانة )السلس البولي(</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>نادرة:</strong></p><p dir="RTL">قد تصيب <strong>حتى</strong><strong> </strong><strong>فرد</strong><strong> </strong><strong>واحد</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 1000</strong> فرد:</p><ul><li dir="RTL">شعور بعدم الراحة وصعوبة في الجلوس أو استمرار الوقوف )تململ(</li><li dir="RTL">نوبات من النشاط الزائد، انشاء واضطراب )هوس(</li><li dir="RTL">نوبات )تشنجات(</li><li dir="RTL">رغبة ملحة لا يمكن مقاومتها لتحريك القدمين )متلازمة عدم راحة القدمين(</li><li dir="RTL">إفراز غير طبيعي لحليب الثدي لدى الرجال والنساء</li><li dir="RTL">اضطرابات الدورة الشهرية )تشمل الدورات الثقيلة، النزف بين الدورات وغياب الدورات(</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>نادرة</strong><strong> </strong><strong>قد</strong><strong> </strong><strong>تظهر</strong><strong> </strong><strong>في</strong><strong> </strong><strong>اختبارات</strong><strong> </strong><strong>الدم</strong><strong>:</strong></p><ul><li dir="RTL">نقص مستوى الصوديوم في الدم )خاصة في كبار السن(</li><li dir="RTL">زيادة في المواد <em>)</em><em>الإنزيمات</em><em> </em><em>(</em>من الكبد</li><li dir="RTL">زيادة في هرمون يدعى برولاكتين</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية نادرة جدا:</strong></p><p dir="RTL">قد تصيب <strong>حتى</strong><strong> </strong><strong>فرد</strong><strong> </strong><strong>واحد</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10000</strong> فرد:</p><ul><li dir="RTL">متلازمة السيروتينين</li><li dir="RTL">طفح جلد، قد يكون مع بثور، ويظهر مثل علامة صغير )بقع صغيرة في الوسط محاطة بمنطقة أفتح مع دائرة داكنة على الحافة( تدعى حمامي عديدة الأشكال</li><li dir="RTL">طفح منتشر مع بثور وجلد متقشر، خصوصا حول الفم، الأنف، العينين والأعضاء التناسلية )متلازمة ستيفنز جونز(</li><li dir="RTL">طفح منتشر مع بثور وجلد متقشر على أغلب سطح الجسم )تنخر الأنسجة الجلدية السام(</li><li dir="RTL">زيادة كميات الهرمون المضاد لإدرار البول الذي يسبب احتباس الماء</li><li dir="RTL">الماء الأزرق )حالة بسبب زيادة ضغط العين(</li><li dir="RTL">نزيف في الجهاز الهضمي )وجود دم في البراز أو براز أسود اللون(</li><li dir="RTL">التهاب الكبد، أحيانا يسبب اصفرار في الجلد أو في بياض العينين )يرقان(</li><li dir="RTL">زيادة حساسية الجلد للضوء</li><li dir="RTL">تورم اليدين، الكاحلين أو القدمين</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>نادرة</strong><strong> </strong><strong>جدا</strong><strong> </strong><strong>قد</strong><strong> </strong><strong>تظهر</strong><strong> </strong><strong>في</strong><strong> </strong><strong>اختبارات</strong><strong> </strong><strong>الدم</strong><strong>:</strong></p><ul><li dir="RTL">نقص في عدد الصفائح الدموية )خلايا تساعد على تخثر الدم(</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>أصبت</strong><strong> </strong><strong>بأعراض</strong><strong> </strong><strong>جانبية</strong></p><p dir="RTL">&nbsp;f <strong>أخبر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong> </strong>إذا كان أي من الأعراض المذكورة أصبحت <strong>شديدة</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>مزعجة</strong>. أو إذا لاحظت أعراض جانبية غير مذكورة في النشرة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض</strong><strong> </strong><strong>تشاهد</strong><strong> </strong><strong>عند</strong><strong> </strong><strong>إيقاف</strong><strong> </strong><strong>سيروكسات</strong></p><p dir="RTL">إيقاف العقاقير التي تستخدم في علاج المشاكل الصحية العقلية غالبا يسبب أعراض جانبية غير مرغوب بها. الأعراض غالبا ما تحدث في الأيام الأولى لتوقف تناول العقار وتختفي بعد أسابيع قليلة.</p><p dir="RTL">إذا كنت تحتاج لإيقاف تناول سيروكسات، قد يخفض طبيبك الجرعة تدريجياً. وهذا يساعد على التقليل من أي آثار وخطورتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض</strong><strong> </strong><strong>شائعة</strong><strong> </strong><strong>تلاحظ</strong><strong> </strong><strong>عند</strong><strong> </strong><strong>إيقاف</strong><strong> </strong><strong>سيروكسات</strong></p><p dir="RTL">تصيب <strong>حتى</strong><strong> </strong><strong>فرد</strong><strong> </strong><strong>واحد</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10</strong> أفراد:</p><ul><li dir="RTL">دوار</li><li dir="RTL">شعور بوخز الإبر، إحساس بصدمات كهربائية وإزعاج مستمر في الأذن )طنين(</li><li dir="RTL">اضطرابات في النوم تشمل الأحلام العميقة</li><li dir="RTL">شعور بالقلق</li><li dir="RTL">صداع</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>شائعة</strong><strong> </strong><strong>تلاحظ</strong><strong> </strong><strong>عند</strong><strong> </strong><strong>إيقاف</strong><strong> </strong><strong>سيروكسات</strong></p><p dir="RTL">تصيب <strong>حتى</strong><strong> </strong><strong>فرد</strong><strong> </strong><strong>واحد</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 100</strong> فرد:</p><ul><li dir="RTL">الشعور بعدم الراحة أو التهيج</li><li dir="RTL">الشعور بالمرض )غثيان(</li><li dir="RTL">رجفان</li><li dir="RTL">الشعور بالإرتباك</li><li dir="RTL">تعرق</li><li dir="RTL">إسهال</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;f<strong>تحدث</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>طبيبك</strong><strong> </strong>إذا أصبحت هذه الأعراض <strong>حادة</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>مزعجة</strong>.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp; </strong><strong>يحفظ</strong><strong> </strong><strong>بعيداً</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>متناول</strong><strong> </strong><strong>ونظر</strong><strong> </strong><strong>الأطفال</strong><strong>.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; لا يجوز استعمال سيروكسات بعد تاريخ انتهاء الصلاحية المبين على العبوة بعد كلمة &quot;Exp&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; يحفظ السيروكسات بدرجة حرارة أقل من 30 &deg;م. قم بحفظه في عبوته الأصلية في مكان جاف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا أخبرك الطبيب بوقف تناول سيروكسات، فمن المهم إعادة أي كمية متبقية إلى الصيدلي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; لا يجوز التخلص من الأدوية في مياه الصرف الصحي أو المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه التدابير تساعد على وقاية البيئة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; يحفظ و يخزن في عبوته الاصلية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">#</p><p dir="RTL"><strong>على ماذا يحتوي سيروكسات</strong></p><p dir="RTL">المادة الفعالة هي پاروكسيتين كپاروكستين هيدروكلورايد هيمي-هيدرات</p><p dir="RTL">أقراص سيروكسات تأتي بتركيزات مختلفة.</p><p dir="RTL">كل قرص يحتوي على:</p><p dir="RTL">20 ملجم من پاروكسيتين</p><p dir="RTL">مواد أخرى غير فعالة:</p><p dir="RTL">قلب القرص: فوسفات الكالسيوم &nbsp;(E341)، هيدروكسي پروپيل ميثيل السيلولوز (E464)، جليكولات نشا الصوديوم، ستياريت الماغنسيوم (E572)</p><p dir="RTL">الغلاف الغشائي: هيدروكسي پروپيل ميثيل السيلولوز (E464)، وثاني أكسيد التيتانيوم (E171) ، وجليكول الپولي إيثيلين، وبوليسوربات 80 (E433).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>على ماذا يحتوي سيروكسات</strong></p><p dir="RTL">المادة الفعالة هي پاروكسيتين كپاروكستين هيدروكلورايد هيمي-هيدرات</p><p dir="RTL">أقراص سيروكسات تأتي بتركيزات مختلفة.</p><p dir="RTL">كل قرص يحتوي على:</p><p dir="RTL">20 ملجم من پاروكسيتين</p><p dir="RTL">مواد أخرى غير فعالة:</p><p dir="RTL">قلب القرص: فوسفات الكالسيوم &nbsp;(E341)، هيدروكسي پروپيل ميثيل السيلولوز (E464)، جليكولات نشا الصوديوم، ستياريت الماغنسيوم (E572)</p><p dir="RTL">الغلاف الغشائي: هيدروكسي پروپيل ميثيل السيلولوز (E464)، وثاني أكسيد التيتانيوم (E171) ، وجليكول الپولي إيثيلين، وبوليسوربات 80 (E433).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>كيف</strong><strong> </strong><strong>يبدو</strong><strong> </strong><strong>شكل</strong><strong> </strong><strong>سيروكسات</strong><strong> </strong><strong>وماهي</strong><strong> </strong><strong>محتويات</strong><strong> </strong><strong>العبوة</strong></p><p dir="RTL">أقراص 20 ملجم: بيضاء، أقراص مغلفة بكسوة غشائية، بيضاوية الشكل، أقراص محدبة.</p><p dir="RTL">أقراص في عبوات فقاعية بشريط ألمنيوم أو قوارير بلاستيكية مع أغطية مقاومة عبث الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تسوق كل العبوات في كل بلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>سيروكسات</em></strong> علامة تجارية مملوكة أو مرخصة لمجموعة شركات جلاكسو سميث كلاين.</p><p dir="RTL">&copy; 2024 مجموعة شركات جلاكسو سميث كلاين، جميع الحقوق محفوظة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تصنيع</strong><strong>:</strong></p><p dir="RTL">ديلفارم بوزنان أسبولكا أكسيجنا، أولي. جرانڤالسكا 189، 60 - 322 بوزنان، بولندا</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تعبئة</strong><strong>:</strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة* جدة، المملكة العربية السعودية</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة</strong><strong> </strong><strong>المالكة</strong><strong> </strong><strong>لرخصة</strong><strong> </strong><strong>التسويق:</strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة* جدة، المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p><p dir="RTL">العنوان: صندوق بريد 22617 ، جدة 21416 ، المملكة العربية السعودية</p><p dir="RTL">*عضو في مجموعة شركات جلاكسو سميث كلاين</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للاستفسار</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>أية</strong><strong> </strong><strong>معلومات</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>المستحضر</strong><strong> </strong><strong>الدوائي،</strong><strong> </strong><strong>يرجى</strong><strong> </strong><strong>الاتصال</strong><strong> </strong><strong>بالأرقام</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL"><strong>جلاكسو سميث كلاين &ndash;المكتب الرئيسي، جدة</strong><strong>.</strong></p><ul><li dir="RTL">هاتف: +966 -12- 6536666</li><li dir="RTL">جوال:&nbsp; +966- 56- 904 9882</li><li dir="RTL">البريد الإلكتروني: &nbsp;&nbsp;&nbsp;<u>gcc.medinfo@gsk.com</u></li><li dir="RTL">الموقع الإلكتروني:&nbsp; <u>https://gskpro.com/en-sa/</u></li><li dir="RTL">ص.ب 55850 ، جدة 21544 ، المملكة العربية السعودية.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:roundrect id="Rectangle_x003a__x0020_Rounded_x0020_Corners_x0020_3"
 o:spid="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:0;margin-top:.45pt;width:456.4pt;height:248pt;z-index:251663360;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:left;mso-position-horizontal-relative:margin;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:middle' arcsize="10923f" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
" fillcolor="window" strokecolor="windowText" strokeweight="1pt">
 <v:stroke joinstyle="miter"/>
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL style='margin-bottom:6.0pt'><b><span lang=AR-SA
    style='font-size:14.0pt;line-height:107%;font-family:"Times New Roman",serif;
    mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
    major-bidi;color:black'>للإبلاغ عن أي آثار جانبية</span></b><span dir=LTR></span><span
    dir=LTR></span><b><span lang=EN-US dir=LTR style='font-size:14.0pt;
    line-height:107%;font-family:"Times New Roman",serif;mso-ascii-theme-font:
    major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
    color:black'><span dir=LTR></span><span dir=LTR></span>:<o:p></o:p></span></b></p>
    <p class=MsoNormal dir=RTL><b><i><span lang=AR-SA style='font-size:14.0pt;
    line-height:107%;font-family:"Times New Roman",serif;mso-ascii-theme-font:
    major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
    color:black'>المملكة العربية السعودية</span></i></b><b><i><span lang=EN-US
    dir=LTR style='font-size:14.0pt;line-height:107%;font-family:"Times New Roman",serif;
    mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
    major-bidi;color:black'><o:p></o:p></span></i></b></p>
    <p class=MsoNormal dir=RTL style='margin-bottom:0in'><b><span lang=EN-US
    dir=LTR style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
    mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
    major-bidi;color:black'>- </span></b><b><span lang=AR-SA style='font-size:
    12.0pt;line-height:107%;font-family:"Times New Roman",serif;mso-ascii-theme-font:
    major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
    color:black'>المركز الوطني للتيقظ والسلامة الدوائية</span></b><span
    dir=LTR></span><span dir=LTR></span><b><span lang=AR-SA dir=LTR
    style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
    mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
    major-bidi;color:black'><span dir=LTR></span><span dir=LTR></span> </span></b><span
    dir=RTL></span><span dir=RTL></span><b><span lang=AR-SA style='font-size:
    12.0pt;line-height:107%;font-family:"Times New Roman",serif;mso-ascii-theme-font:
    major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
    color:black'><span dir=RTL></span><span dir=RTL></span>(</span></b><b><span
    lang=EN-US dir=LTR style='font-size:12.0pt;line-height:107%;font-family:
    "Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:
    major-bidi;mso-bidi-theme-font:major-bidi;color:black'>NPC</span></b><span
    dir=RTL></span><span dir=RTL></span><b><span lang=AR-SA style='font-size:
    12.0pt;line-height:107%;font-family:"Times New Roman",serif;mso-ascii-theme-font:
    major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
    color:black'><span dir=RTL></span><span dir=RTL></span>)</span></b><b><span
    lang=AR-EG style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
    mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
    major-bidi;color:black;mso-bidi-language:AR-EG'><o:p></o:p></span></b></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.5in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;mso-add-space:auto;
    text-align:right;text-indent:-.25in;line-height:normal;mso-pagination:widow-orphan;
    mso-list:l1 level1 lfo1;mso-layout-grid-align:none;direction:rtl;
    unicode-bidi:embed'><![if !supportLists]><span style='font-size:12.0pt;
    mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
    mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
    mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
    mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    color:black;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>الاتصال
    بالرقم الموحد: 19999</span><span dir=LTR style='mso-ascii-font-family:"Times New Roman";
    mso-ascii-theme-font:major-bidi;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
    minor-latin;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:
    major-bidi;mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    color:black;mso-fareast-language:EN-US'><o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.5in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;mso-add-space:auto;
    text-align:right;text-indent:-.25in;line-height:normal;mso-pagination:widow-orphan;
    mso-list:l1 level1 lfo1;mso-layout-grid-align:none;direction:rtl;
    unicode-bidi:embed'><![if !supportLists]><span style='font-size:12.0pt;
    mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
    mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
    mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
    mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    color:black;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>البريد
    الإلكتروني: </span><span dir=LTR></span><span dir=LTR></span><span
    lang=AR-SA dir=LTR style='mso-ascii-font-family:"Times New Roman";
    mso-ascii-theme-font:major-bidi;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
    minor-latin;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:
    major-bidi;mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    mso-fareast-language:EN-US'><span dir=LTR></span><span dir=LTR></span><span
    style='mso-spacerun:yes'> </span></span><span class=MsoHyperlink><span
    dir=LTR style='mso-fareast-font-family:"Times New Roman";mso-fareast-theme-font:
    minor-fareast'>npc.drug@sfda.gov.sa</span></span><span dir=LTR
    style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
    mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
    mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
    mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    mso-fareast-language:EN-US'><o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.5in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;mso-add-space:auto;
    text-align:right;text-indent:-.25in;line-height:normal;mso-pagination:widow-orphan;
    mso-list:l1 level1 lfo1;mso-layout-grid-align:none;direction:rtl;
    unicode-bidi:embed'><![if !supportLists]><span style='font-size:12.0pt;
    mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
    mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
    mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
    mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>الموقع الإلكتروني: </span><a
    href="https://ade.sfda.gov.sa"><span dir=LTR style='mso-fareast-font-family:
    "Times New Roman";mso-fareast-theme-font:minor-fareast'>https://ade.sfda.gov.sa</span></a><span
    dir=LTR style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
    major-bidi;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
    mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
    mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    mso-fareast-language:EN-US'><o:p></o:p></span></p>
    <p class=MsoListParagraph style='margin-left:.5in;mso-add-space:auto;
    line-height:normal;mso-layout-grid-align:none'><b><span lang=AR-EG dir=RTL
    style='font-size:8.0pt;font-family:TraditionalArabic-Bold;mso-ascii-font-family:
    TraditionalArabic-Bold;mso-bidi-language:AR-EG'><o:p>&nbsp;</o:p></span></b></p>
    <p class=MsoNormal dir=RTL style='margin-bottom:0in'><b><span lang=AR-SA
    style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
    mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
    major-bidi'>جلاكسو سميث كلاين – المكتب الرئيسي، جدة</span></b><span
    dir=LTR></span><span dir=LTR></span><b><span lang=EN-US dir=LTR
    style='font-size:12.0pt;line-height:107%;font-family:"Times New Roman",serif;
    mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:
    major-bidi;color:black'><span dir=LTR></span><span dir=LTR></span>.<o:p></o:p></span></b></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.5in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;mso-add-space:auto;
    text-align:right;text-indent:-.25in;line-height:normal;mso-pagination:widow-orphan;
    mso-list:l0 level1 lfo2;mso-layout-grid-align:none;direction:rtl;
    unicode-bidi:embed'><![if !supportLists]><span style='font-size:12.0pt;
    mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
    mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
    mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
    mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    color:black;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>هاتف:
    6536666 </span><span dir=LTR></span><span dir=LTR></span><span dir=LTR
    style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
    mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
    mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
    mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    color:black;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><span
    dir=LTR></span><span dir=LTR></span>-</span><span dir=RTL></span><span
    dir=RTL></span><span lang=AR-SA style='mso-ascii-font-family:"Times New Roman";
    mso-ascii-theme-font:major-bidi;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
    minor-latin;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:
    major-bidi;mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    color:black;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><span
    dir=RTL></span><span dir=RTL></span>12</span><span dir=LTR></span><span
    dir=LTR></span><span dir=LTR style='mso-ascii-font-family:"Times New Roman";
    mso-ascii-theme-font:major-bidi;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
    minor-latin;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:
    major-bidi;mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    color:black;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><span
    dir=LTR></span><span dir=LTR></span>-</span><span dir=RTL></span><span
    dir=RTL></span><span lang=AR-SA style='mso-ascii-font-family:"Times New Roman";
    mso-ascii-theme-font:major-bidi;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
    minor-latin;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:
    major-bidi;mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    color:black;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><span
    dir=RTL></span><span dir=RTL></span> 966</span><span dir=LTR></span><span
    dir=LTR></span><span dir=LTR style='mso-ascii-font-family:"Times New Roman";
    mso-ascii-theme-font:major-bidi;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
    minor-latin;mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:
    major-bidi;mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    color:black;mso-fareast-language:EN-US'><span dir=LTR></span><span dir=LTR></span>
    +<o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.5in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;mso-add-space:auto;
    text-align:right;text-indent:-.25in;line-height:normal;mso-pagination:widow-orphan;
    mso-list:l0 level1 lfo2;mso-layout-grid-align:none;direction:rtl;
    unicode-bidi:embed'><![if !supportLists]><span style='font-size:12.0pt;
    mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
    mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
    mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
    mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    color:black;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>المحمول :
    9882 - 904 - 56 966</span><span dir=LTR></span><span dir=LTR></span><span
    dir=LTR style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
    major-bidi;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
    mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
    mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    color:black;mso-fareast-language:EN-US'><span dir=LTR></span><span dir=LTR></span>
    +<o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.5in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;mso-add-space:auto;
    text-align:right;text-indent:-.25in;line-height:normal;mso-pagination:widow-orphan;
    mso-list:l0 level1 lfo2;mso-layout-grid-align:none;direction:rtl;
    unicode-bidi:embed'><![if !supportLists]><span style='font-size:12.0pt;
    mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
    mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
    mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
    mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    color:black;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>البريد الإلكتروني:
    </span><span dir=LTR></span><span dir=LTR></span><span lang=AR-SA dir=LTR
    style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
    mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
    mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
    mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    color:black;mso-fareast-language:EN-US'><span dir=LTR></span><span dir=LTR></span><span
    style='mso-spacerun:yes'> </span></span><span class=MsoHyperlink><span
    dir=LTR style='mso-fareast-font-family:"Times New Roman";mso-fareast-theme-font:
    minor-fareast'>saudi.safety@gsk.com</span></span><span dir=LTR
    style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
    mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
    mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
    mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    mso-fareast-language:EN-US'><o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.5in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;mso-add-space:auto;
    text-align:right;text-indent:-.25in;line-height:normal;mso-pagination:widow-orphan;
    mso-list:l0 level1 lfo2;mso-layout-grid-align:none;direction:rtl;
    unicode-bidi:embed'><![if !supportLists]><span style='font-size:12.0pt;
    mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol;mso-fareast-language:EN-US'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
    mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
    mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
    mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>الموقع الإلكتروني: </span><span
    dir=LTR></span><span dir=LTR></span><span lang=AR-SA dir=LTR><span dir=LTR></span><span
    dir=LTR></span><span style='mso-spacerun:yes'> </span></span><span
    class=MsoHyperlink><span dir=LTR style='mso-fareast-font-family:"Times New Roman";
    mso-fareast-theme-font:minor-fareast'>https://gskpro.com/en-sa/</span></span><span
    dir=LTR style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:
    major-bidi;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
    mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
    mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    mso-fareast-language:EN-US'> <o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:.5in;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;mso-add-space:auto;
    text-align:right;text-indent:-.25in;line-height:normal;mso-list:l0 level1 lfo2;
    mso-layout-grid-align:none;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:12.0pt;mso-bidi-font-size:11.0pt;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
    mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
    mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
    mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi;
    mso-fareast-language:EN-US;mso-bidi-language:AR-SA'>ص.ب 55850 ، جدة 21544 <span
    style='color:black'>، المملكة العربية السعودية</span></span><span dir=LTR
    style='mso-ascii-font-family:"Times New Roman";mso-ascii-theme-font:major-bidi;
    mso-hansi-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
    mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:major-bidi'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:roundrect><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="613" height="335" alt="Rectangle: Rounded Corners: للإبلاغ عن أي آثار جانبية:
المملكة العربية السعودية
- المركز الوطني للتيقظ والسلامة الدوائية (NPC)
•	الاتصال بالرقم الموحد: 19999
•	البريد الإلكتروني:  npc.drug@sfda.gov.sa
•	الموقع الإلكتروني: https://ade.sfda.gov.sa

جلاكسو سميث كلاين – المكتب الرئيسي، جدة.
•	هاتف: 6536666 -12- 966 +
•	المحمول : 9882 - 904 - 56 966 +
•	البريد الإلكتروني:  saudi.safety@gsk.com
•	الموقع الإلكتروني:  https://gskpro.com/en-sa/ 
•	ص.ب 55850 ، جدة 21544 ، المملكة العربية السعودية
" src="file:///C:/Users/aa630244/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            رقم: GDS48
تاريخ الإصدار:  8ديسمبر2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Paroxetine hydrochloride hemihydrate
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each SEROXAT tablet contains paroxetine hydrochloride hemihydrate equivalent to 20 mg paroxetine free base.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                White, film-coated, oval shaped, biconvex tablets with a break line on one side. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adults</strong></p><p><strong>&nbsp;</strong></p><p><strong>Major Depressive Disorder:</strong></p><p><strong>&nbsp;</strong></p><p><em>SEROXAT </em>is indicated for the treatment of major depressive disorder (MDD). Results of studies in which patients received <em>SEROXAT </em>treatment for up to one year indicate that <em>SEROXAT </em>is effective in preventing the relapse and also recurrence of depressive symptoms.</p><p>&nbsp;</p><p><strong>Anxiety Disorders:</strong><!--[if supportFields]><b><span style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_6f5a2cfd-d6a9-4c3b-9956-d8141d92ebe2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Treatment of symptoms and prevention of relapse of Obsessive-Compulsive Disorder (OCD).</p><p>&nbsp;</p><p>Treatment of symptoms and prevention of relapse of Panic Disorder with or without agoraphobia.</p><p>&nbsp;</p><p>Treatment of Social Anxiety Disorder/Social Phobia.</p><p>&nbsp;</p><p>Treatment of symptoms and prevention of relapse of Generalised Anxiety Disorder. Treatment of Post-Traumatic Stress Disorder.</p><p><strong>Children and adolescents (less than 18 years) All Indications:</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_2579be8c-f3bd-4491-be1b-a2bde0e6c014 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><em>SEROXAT </em>is not indicated for use in children or adolescents aged less than 18 years (<em>see Special warnings and precautions for use</em>).</p><p>Controlled clinical studies in children and adolescents with major depressive disorder failed to demonstrate efficacy, and do not support the use of <em>SEROXAT </em>in the treatment of depression in this population (<em>see Special warnings and precautions for use</em>).</p><p>&nbsp;</p><p>The safety and efficacy of <em>SEROXAT </em>in children aged less than 7 years has not been studied.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Method of Administration:</p><p>&bull; <em>Seroxat </em>is a Hazardous drug. Recommended to follow applicable special handling and disposal procedures (see section 6.4).</p><p><strong>Adults</strong></p><p><strong>&nbsp;</strong></p><p>For oral administration.</p><p>&nbsp;</p><p>It is recommended that <em>SEROXAT </em>be administered once daily in the morning with food.</p><p>&nbsp;</p><p>The tablets should be swallowed rather than chewed. The 20 mg tablets have functional break lines to allow for breaking the tablets in half to yield 10 mg doses, if needed.</p><p>&nbsp;</p><p>As with all antidepressant drugs, dosage should be reviewed and adjusted, if necessary, within 2 to 3 weeks of initiation of therapy and thereafter as judged clinically appropriate. Patients should be treated for a sufficient period to ensure that they are free from symptoms. This period may be several months for depression and may be even longer for OCD and panic disorder. As with many psychoactive medications, abrupt discontinuation should be avoided (<em>see Adverse Reactions</em>).</p><p>&nbsp;</p><p><strong>Major Depressive Disorder:</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b25fcbc9-c83b-4cc1-a1a8-9f64d3159f0b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>The recommended dose is 20 mg daily. In some patients it may be necessary to increase the dose. This should be done gradually by 10 mg increments to a maximum of 50 mg according to the patient&rsquo;s response.</p><p>&nbsp;</p><p><strong>Obsessive Compulsive Disorder:</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_7511af05-8eff-4194-b1d6-ba9e4013e508 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>The recommended dose is 40 mg daily. Patients should start on 20 mg daily and the dose may be increased weekly in 10 mg increments. Some patients will benefit from having their dose increased up to a maximum of 60 mg daily.</p><p>&nbsp;</p><p><strong>Panic Disorder:</strong><!--[if supportFields]><b><span style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_658bf046-9e2c-47d6-8655-83f6cc05a5e8 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>The recommended dose is 40 mg daily. Patients should be started on 10 mg daily and the dose increased weekly in 10 mg increments according to the patient&#39;s response. Some patients may benefit from having their dose increased up to a maximum of 60 mg daily. As is generally recognised, there is the potential for worsening of panic symptomatology during early treatment of panic disorder; a low initial starting dose is therefore recommended.</p><p>&nbsp;</p><p><strong>Social Anxiety Disorder/Social Phobia:</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_015e5f9c-39c4-4847-8ab1-a8f97cc52a15 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>The recommended dose is 20 mg daily. Patients not responding to a 20 mg dose may benefit from dose increases in 10 mg increments as required, up to a maximum of</p><p>50 mg/day. Dose changes should occur at intervals of at least 1 week according to the patient&#39;s response.</p><p>&nbsp;</p><p><strong>Generalised Anxiety Disorder:</strong><!--[if supportFields]><b><span style='font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_ee1a1cd3-8c9f-4a0c-95a7-740f9746770c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>The recommended dose is 20 mg daily. Some patients not responding to a 20 mg dose may benefit from having dose increases in 10 mg increments as required, up to a</p><p>maximum of 50 mg/day according to patient&rsquo;s response.</p><p>&nbsp;</p><p><strong>Post-Traumatic Stress Disorder:</strong><!--[if supportFields]><b><span style='font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_8926dec5-bb1f-4076-90a9-eef9d013aee5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>The recommended dose is 20 mg daily. Some patients not responding to a 20 mg dose may benefit from having dose increases in 10 mg increments as required, up to a</p><p>maximum of 50 mg/day according to the patient&rsquo;s response.</p><p>&nbsp;</p><p><strong>General Information DISCONTINUATION OF <em>SEROXAT</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;line-height:
190%;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_910e21a2-c1a5-4b39-91ee-f5440af56bdd \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><b><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;line-height:
190%;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></i></b><![endif]--></p><p>As with other psychoactive medications, abrupt discontinuation should generally be avoided (<em>see Special warnings and precautions for use and Adverse Reactions</em>). The taper phase regimen used in recent clinical trials involved a decrease in the daily dose by 10 mg/day at weekly intervals.</p><p>&nbsp;</p><p>&nbsp;</p><p>When a daily dose of 20 mg/day was reached, patients were continued on this dose for one week before treatment was stopped. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.</p><p>&nbsp;</p><p><strong>Other populations</strong><!--[if supportFields]><b><span style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_f9d79214-1236-4f4e-86c6-b355806eb7f1 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p><em>Elderly:</em></p><p><em>&nbsp;</em></p><p>Increased plasma concentrations of paroxetine occur in elderly subjects, but the range of concentrations overlaps with that observed in younger subjects.</p><p>&nbsp;</p><p>Dosing should commence at the adult starting dose and may be increased weekly in 10 mg increments to a maximum of 40 mg daily according to the patient&#39;s response.</p><p>&nbsp;</p><p><em>Children and adolescents (less than 18 years):</em></p><p><em>&nbsp;</em></p><p><em>SEROXAT </em>is not indicated for use in children or adolescents aged less than 18 years (<em>see Indications, Special warnings and precautions for use</em>).</p><p>&nbsp;</p><p><em>Renal/hepatic impairment:</em></p><p><em>&nbsp;</em></p><p>Increased plasma concentrations of paroxetine occur in patients with severe renal impairment (creatinine clearance &lt;30 mL/min) or in those with hepatic impairment. The recommended dose is 20 mg daily. Incremental dosage, if required, should be restricted to the lower end of the range.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Known hypersensitivity to paroxetine and excipients.

SEROXAT should not be used in combination with monoamine oxidase (MAO) inhibitors (including linezolid, an antibiotic which is a reversible non-selective MAO inhibitor and methylthioninium chloride (methylene blue)) or within two weeks of terminating treatment with MAO inhibitors. Likewise, MAO inhibitors should not be introduced within two weeks of cessation of therapy with SEROXAT (see Interactions).

SEROXAT should not be used in patients receiving medications that can prolong QT interval and are also metabolised by CYP450 2D6, such as thioridazine or pimozide (see Interactions

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Children and Adolescents (less than 18 years)</strong></p><p><strong>&nbsp;</strong></p><p>Treatment with antidepressants is associated with an increased risk of suicidal thinking and behaviour in children and adolescents with Major Depressive Disorder (MDD) and other psychiatric disorders. In clinical trials of <em>SEROXAT </em>in children and adolescents, adverse events related to suicidality (suicide attempts and suicidal thoughts) and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed in patients treated with <em>SEROXAT </em>compared to those treated with placebo <em>(see Adverse Reactions). </em>Long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural development are lacking.</p><p>&nbsp;</p><p><strong>Clinical worsening and suicide risk in adults</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_7983dee9-c97d-4edf-ae29-74b78ddbfc65 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Young adults, especially those with MDD, may be at increased risk for suicidal behaviour during treatment with <em>SEROXAT</em>. An analysis of placebo-controlled trials of adults with psychiatric disorders showed a higher frequency of suicidal behaviour in young adults (prospectively defined as aged 18 to 24 years) treated with paroxetine compared with placebo (17/776 [2.19%] versus 5/542 [0.92%]), although this difference was not statistically significant. In the older age groups (aged 25 to 64 years and &ge;65 years), no such increase was observed. In adults with MDD (all ages), there was a statistically significant increase in the frequency of suicidal behaviour in patients treated with paroxetine compared with placebo (11/3455 [0.32%] versus 1/1978 [0.05%]; all of the events were suicide attempts). However, the majority of these attempts for paroxetine</p><p>(8 of 11) were in younger adults aged 18 to 30 years. These MDD data suggest that the higher frequency observed in the younger adult population across psychiatric disorders may extend beyond the age of 24.</p><p>Patients with depression may experience worsening of their depressive symptoms and/or the emergence of suicidal ideation and behaviours (suicidality) whether or not they are taking antidepressant medications. This risk persists until significant remission occurs. It is general clinical experience with all antidepressant therapies that the risk of suicide may increase in the early stages of recovery. Other psychiatric conditions for which <em>SEROXAT </em>is prescribed can be associated with an increased risk of suicidal behaviour, and these conditions may also be co-morbid with MDD. Additionally, patients with a history of suicidal behaviour or thoughts, young adults, and those patients exhibiting a significant degree of suicidal ideation prior to commencement of treatment, are at a greater risk of suicidal thoughts or suicide attempts. All patients should be monitored for clinical worsening (including development of new symptoms) and suicidality throughout treatment, and especially at the beginning of a course of treatment, or at the time of dose changes, either increases or decreases.</p><p>&nbsp;</p><p>Patients (and caregivers of patients) should be alerted about the need to monitor for any worsening of their condition (including development of new symptoms) and/or the emergence of suicidal ideation/behaviour or thoughts of harming themselves and to seek medical advice immediately if these symptoms present. It should be recognised that the onset of some symptoms, such as agitation, akathisia or mania, could be related either to the underlying disease state or the drug therapy (<em>see Akathisia and Mania and Bipolar Disorder below; Adverse Reactions</em>).</p><p>&nbsp;</p><p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients who experience clinical worsening (including development of new symptoms) and/or the emergence of suicidal ideation/behaviour, especially if these symptoms are severe, abrupt in onset, or were not part of the patient&rsquo;s presenting symptoms.</p><p><strong>&nbsp;</strong></p><p><strong>Akathisia</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_88a78d56-335e-49be-94c6-78ca489cf2ee \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Rarely, the use of <em>SEROXAT </em>or other selective serotonin reuptake inhibitors (SSRIs) have been associated with the development of akathisia, which is characterised by an inner sense of restlessness and psychomotor agitation such as an inability to sit or stand still usually associated with subjective distress. This is most likely to occur within the first few weeks of treatment.</p><p>&nbsp;</p><p><strong>Serotonin Syndrome/Neuroleptic Malignant Syndrome</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_5af0f209-d4ff-4516-9623-885de5c5f4b1 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>On rare occasions development of a serotonin syndrome or neuroleptic malignant syndrome-like events may occur in association with <em>SEROXAT </em>treatment, particularly when given in combination with other serotonergic and/or neuroleptic drugs. As these syndromes may result in potentially life-threatening conditions, treatment with <em>SEROXAT </em>should be discontinued if such events (characterised by clusters of symptoms such as hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes including confusion, irritability, extreme agitation progressing to delirium and coma) occur and supportive symptomatic treatment should be initiated. <em>SEROXAT </em>should not be used in combination with serotonin-precursors (such as L-tryptophan, oxitriptan) due to the risk of serotonergic syndrome (<em>see Contraindications, Interactions</em>).</p><p><strong>Mania and Bipolar disorder</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_da3b0177-5f7b-445c-8576-0848f4e0b962 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone can increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Prior to initiating treatment with an antidepressant, patients should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that <em>SEROXAT </em>is not approved for use in treating bipolar depression. As with all antidepressants, paroxetine should be used with caution in patients with a history of mania.</p><p><strong>Tamoxifen</strong></p><p>Some studies have shown that the efficacy of tamoxifen, as measured by the risk of breast cancer relapse/mortality, may be reduced when co-prescribed with <em>SEROXAT </em>as a result of paroxetine&rsquo;s irreversible inhibition of CYP2D6 (<em>see Interactions</em>). This risk may increase with longer duration of co-administration. When tamoxifen is used for the treatment or prevention of breast cancer; prescribers should consider using an alternative antidepressant with little or no CYP2D6 inhibition.</p><p>&nbsp;</p><p><strong>Bone fracture</strong><!--[if supportFields]><b><span style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_f9b9aadb-b9e4-4856-9b40-3ebb0e0e6df9 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Epidemiological studies on bone fracture risk following exposure to some antidepressants, including SSRIs, have reported an association with fractures. The risk occurs during treatment and is greatest in the early stages of therapy. The possibility of fracture should be considered in the care of patients treated with <em>SEROXAT</em>.</p><p>&nbsp;</p><p><strong>Monoamine Oxidase Inhibitors</strong><!--[if supportFields]><b><span style='font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_988bd581-69ef-4254-b316-5ddbb1f5a767 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Treatment with <em>SEROXAT </em>should be initiated cautiously at least 2 weeks after terminating treatment with MAO inhibitors and dosage of <em>SEROXAT </em>should be increased gradually until optimal response is reached (<em>see Contraindications, Interactions</em>).</p><p>&nbsp;</p><p><strong>Renal/hepatic impairment</strong><!--[if supportFields]><b><span style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_7783096d-a9fb-4ec1-9ea7-a0705c02631d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Caution is recommended in patients with severe renal impairment or in those with hepatic impairment (<em>see Dosage and Administration</em>).</p><p>&nbsp;</p><p><strong>Epilepsy</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_94f0ca4e-a435-45c1-bc0d-79c26156f880 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>As with other antidepressants, <em>SEROXAT </em>should be used with caution in patients with epilepsy.</p><p>&nbsp;</p><p><strong>Seizures</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_7047b8f7-7e09-4794-9936-e9cf08df2323 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Overall, the incidence of seizures is less than 0.1% in patients treated with <em>SEROXAT</em>. <em>SEROXAT </em>should be discontinued in any patient who develops seizures.</p><p><strong>Glaucoma</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_038d0d26-60ca-4d4f-97b9-a2bb21d1641a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>As with other SSRIs, <em>SEROXAT </em>can cause mydriasis and should be used with caution in patients with narrow angle glaucoma<em>.</em></p><p><em>&nbsp;</em></p><p><strong>Electroconvulsive therapy (ECT)</strong><!--[if supportFields]><b><span style='font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_87a76369-ce39-4e85-aa8a-a35848d316d1 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>There is little clinical experience of the concurrent administration of <em>SEROXAT </em>with ECT. However, there have been rare reports of prolonged ECT-induced seizures and/or secondary seizures in patients on SSRIs.</p><p>&nbsp;</p><p><strong>Hyponatraemia</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_5dd01de9-e9df-46fc-86f5-86905882d80a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Hyponatraemia has been reported rarely, predominantly in the elderly. The hyponatraemia generally reverses on discontinuation of paroxetine.</p><p>&nbsp;</p><p><strong>Haemorrhage</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_9f810647-3727-493a-b6c6-da08efa66ead \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>Skin and mucous membrane bleedings (including gastrointestinal and gynaecological bleeding) have been reported following treatment with <em>SEROXAT</em>. <em>SEROXAT</em><em> </em>should therefore be used with caution in patients concomitantly treated with drugs that give an increased risk for bleeding, and in patients with a known tendency for bleeding or those with predisposing conditions (<em>see Adverse Reactions</em>). SSRIs may increase the risk of postpartum haemorrhage <em>(see Fertility, Pregnancy and Lactation)</em>.</p><p><strong>Cardiac Conditions</strong><!--[if supportFields]><b><span style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_8508d267-2c00-418b-9c10-f30c6bb5901a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>The usual precautions should be observed in patients with cardiac conditions.</p><p>&nbsp;</p><p><strong>QT Prolongation</strong></p><p><strong>&nbsp;</strong></p><p>Cases of QT interval prolongation have been reported, although causality with paroxetine has not been established.</p><p>&nbsp;</p><p><em>SEROXAT</em> should be used with caution in patients with a history of QT interval prolongation, patients taking anti-arrhythmic or other medications that may potentially prolong QT interval, or those with relevant pre-existing cardiac disease.</p><p>&nbsp;</p><p>For further information, <em>see Contraindications and Interactions</em>.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Symptoms seen on discontinuation of <em>SEROXAT </em>treatment in adults:</strong><!--[if supportFields]><b><span style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_74641f09-ed5f-42d5-af0c-fa73438719ba \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>In clinical trials in adults, adverse events seen on treatment discontinuation occurred in 30% of patients treated with <em>SEROXAT </em>compared to 20% of patients treated with placebo. The occurrence of discontinuation symptoms is not the same as the drug being addictive or dependence producing as with a substance of abuse.</p><p>&nbsp;</p><p>Dizziness, sensory disturbances (including paraesthesia, electric shock sensations and tinnitus), sleep disturbances (including intense dreams), agitation or anxiety, nausea, tremor, confusion, sweating, headache, diarrhoea have been reported. Generally, these symptoms are mild to moderate, however, in some patients they may be severe in intensity. They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose. Generally, these symptoms are self-limiting and usually resolve within two weeks, though in some individuals they may be prolonged (two to three months or more). It is therefore advised that <em>SEROXAT </em>should be gradually tapered when discontinuing treatment over a period of several weeks or months, according to the patient&#39;s needs (<em>see &quot;Discontinuation of SEROXAT&quot;, Dosage and Administration</em>).</p><p><strong>Sexual dysfunction</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_24835861-26a0-4d17-a6fc-7d0798e4ddcb
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>&nbsp;</p><p>SSRIs may cause symptoms of sexual dysfunction (See Adverse Reactions). There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs.</p><p>&nbsp;</p><p><strong>Symptoms seen on discontinuation of <em>SEROXAT </em>treatment in children and adolescents:</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c28047fd-09e4-41f6-833a-e96d920ed0e2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>In clinical trials in children and adolescents, adverse events seen on treatment discontinuation occurred in 32% of patients treated with <em>SEROXAT </em>compared to 24% of patients treated with placebo. Events reported upon discontinuation of <em>SEROXAT </em>at a frequency of at least 2% of patients and which occurred at a rate at least twice that of placebo were: emotional lability (including suicidal ideation, suicide attempt, mood changes and tearfulness), nervousness, dizziness, nausea and abdominal pain (<em>see Adverse Reactions</em>).</p><p><!--[if gte vml 1]><v:shape
 id="Freeform_x003a__x0020_Shape_x0020_5" o:spid="_x0000_s1026" style='position:absolute;
 left:0;text-align:left;margin-left:463.85pt;margin-top:23.55pt;width:3pt;
 height:1.75pt;z-index:-251656192;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top'
 coordsize="60,35" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" path="m60,27l,27r,8l60,35r,-8m60,l,,,8r60,l60,e" fillcolor="black" stroked="f">
 <v:path arrowok="t" o:connecttype="custom" o:connectlocs="24193500,200806050;0,200806050;0,204031850;24193500,204031850;24193500,200806050;24193500,189918975;0,189918975;0,193144775;24193500,193144775;24193500,189918975"
  o:connectangles="0,0,0,0,0,0,0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="4" height="3" src="file:///C:/Users/aa630244/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><em>SEROXAT </em>liquid contains methyl and propyl parahydroxybenzoate (parabens), which are known to cause urticaria, delayed type reactions such as contact dermatitis and rarely, immediate hypersensitivity reactions with bronchospasm.</p><p>&nbsp;</p><p>In patients receiving <em>SEROXAT </em>liquid, the paroxetine plasma concentration may be influenced by gastric pH. <em>In vitro </em>data have shown that an acidic environment is required for release of the active drug from the liquid, hence absorption may be reduced in patients with a high gastric pH. Caution is therefore required because in certain situations the plasma paroxetine concentration may increase (e.g. following discontinuation of a proton pump inhibitor or a histamine H2-receptor antagonist) or the plasma paroxetine concentration may decrease (e.g. in patients with a high gastric pH changing therapy from tablet to the liquid formulation).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Serotonergic drugs</strong></p><p><strong>&nbsp;</strong></p><p>As with other SSRIs, co-administration with serotonergic drugs may lead to an incidence of 5-HT associated effects (serotonin syndrome: <em>see Special warnings and precautions for use</em>). Caution should be advised, and a closer clinical monitoring is required when serotonergic drugs (such as L-tryptophan, triptans, tramadol, SSRIs, lithium, fentanyl and St. John&#39;s Wort &ndash; <em>Hypericum perforatum </em>&ndash; preparations) are combined with <em>SEROXAT</em>.</p><p>&nbsp;</p><p>Concomitant use of <em>SEROXAT </em>and MAO inhibitors (including linezolid, an antibiotic which is a reversible non-selective MAO inhibitor and methylthioninium chloride (methylene blue)) is contraindicated (<em>see Contraindications</em>).</p><p>&nbsp;</p><p><strong>Pimozide</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c98bf03e-7388-4186-9846-fb63d833bb53 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Increased pimozide levels have been demonstrated in a study of a single low dose pimozide (2 mg) when co-administered with paroxetine. This is explained by the known CYP2D6 inhibitory properties of paroxetine. Due to the narrow therapeutic index of pimozide and its known ability to prolong QT interval, concomitant use of pimozide and <em>SEROXAT </em>is contraindicated (<em>see Contraindications</em>).</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Drug metabolising enzymes</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_0f66555f-d3ab-4aee-9935-12daca9bed15 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>The metabolism and pharmacokinetics of paroxetine may be affected by the induction or inhibition of drug metabolising enzymes.</p><p>&nbsp;</p><p>When <em>SEROXAT </em>is to be co-administered with a known drug metabolising enzyme inhibitor, consideration should be given to using doses at the lower end of the range. No initial dosage adjustment is considered necessary when the drug is to be co- administered with known drug metabolising enzyme inducers (e.g. carbamazepine, rifampicin, phenobarbital, phenytoin). Any subsequent dosage adjustment should be guided by clinical effect (tolerability and efficacy).</p><p>&nbsp;</p><p><em>Fosamprenavir/ritonavir: </em>Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Procyclidine</em>: Daily administration of paroxetine increases significantly the plasma levels of procyclidine. If anti-cholinergic effects are seen, the dose of procyclidine should be reduced.</p><p>&nbsp;</p><p><em>Anticonvulsants</em>: carbamazepine, phenytoin, sodium valproate. Concomitant administration does not seem to show any effect on pharmacokinetic/dynamic profile in epileptic patients.</p><p>&nbsp;</p><p><strong>Neuromuscular Blockers</strong><!--[if supportFields]><b><span style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_5a31bc66-f1e3-49a5-a44d-6e7d520c3c5a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>SSRIs may reduce plasma cholinesterase activity resulting in a prolongation of the neuromuscular blocking action of mivacurium and suxamethonium.</p><p>&nbsp;</p><p><strong>CYP2D6 inhibitory potency of paroxetine</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_505fa5e5-2059-45fe-9ba0-3101d9ea1d7d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>As with other antidepressants, including other SSRIs, paroxetine inhibits the hepatic cytochrome P450 enzyme CYP2D6. Inhibition of CYP2D6 may lead to increased plasma concentrations of co-administered drugs metabolised by this enzyme. These include certain tricyclic antidepressants (e.g. amitriptyline, nortriptyline, imipramine and desipramine), phenothiazine neuroleptics (e.g. perphenazine and thioridazine, <em>see Contraindications</em>), risperidone, atomoxetine, certain Type 1c antiarrhythmics (e.g. propafenone and flecainide) and metoprolol.</p><p>Tamoxifen has an important active metabolite, endoxifen, which is produced by CYP2D6 and contributes significantly to the efficacy of tamoxifen. Irreversible inhibition of CYP2D6 by paroxetine leads to reduced plasma concentrations of endoxifen (<em>see Special warnings and precautions for use</em>).</p><p>&nbsp;</p><p><strong>CYP3A4</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_6a929433-ede4-4cc4-9686-27c98dff1c59 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>An <em>in vivo </em>interaction study involving the co-administration under steady state conditions of paroxetine and terfenadine, a substrate for cytochrome CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics. A similar <em>in vivo </em>interaction study revealed no effect of paroxetine on alprazolam pharmacokinetics and vice-versa. Concurrent administration of paroxetine with terfenadine, alprazolam and other drugs that are CYP3A4 substrates would not be expected to cause a hazard.</p><p>&nbsp;</p><p><strong>Drugs affecting gastric pH</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_7ef71084-e52e-4e26-a7ea-9bae57918459 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p><em>In vitro </em>data have shown that dissociation of paroxetine from the oral liquid is</p><p>pH-dependant. Therefore, drugs that alter gastric pH (such as proton pump inhibitors or histamine H2-receptor antagonists) may affect plasma paroxetine concentrations in patients taking the oral liquid (<em>see Special warnings and precautions for use</em>).</p><p>&nbsp;</p><p>Clinical studies have shown the absorption and pharmacokinetics of paroxetine to be unaffected or only marginally affected (i.e. at a level which warrants no change in dosing regimen) by:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>food</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_f1cf42f0-1386-417c-8792-44657474a277 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>antacids</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>digoxin</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>propranolol</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>alcohol</strong>: paroxetine does not increase the impairment of mental and motor skills caused by alcohol, however, the concomitant use of <em>SEROXAT </em>and alcohol is not advised.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Fertility</strong></p><p><strong>&nbsp;</strong></p><p>Some clinical studies have shown that SSRIs (including <em>SEROXAT</em>) may affect sperm quality. This effect appears to be reversible following discontinuation of treatment.</p><p>Changes in sperm quality may affect fertility in some men.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p><strong>&nbsp;</strong></p><p>Animal studies have not shown any teratogenic or selective embryotoxic effects.</p><p>&nbsp;</p><p>Epidemiological studies of pregnancy outcomes following maternal exposure to antidepressants in the first trimester have reported an increase in the risk of congenital malformations, particularly cardiovascular (e.g. ventricular and atrial septal defects), associated with the use of paroxetine. The data suggest that the risk of having an infant with a cardiovascular defect following maternal paroxetine exposure is</p><p>approximately 1/50, compared with an expected rate for such defects of approximately 1/100 infants in the general population.</p><p>The prescribing physician will need to weigh the option of alternative treatments in women who are pregnant or are planning to become pregnant, and should only prescribe <em>SEROXAT </em>if the potential benefit outweighs the potential risk. If a decision is taken to discontinue <em>SEROXAT </em>treatment in a pregnant woman, the prescriber should consult <em>Dosage and Administration - Discontinuation of SEROXAT </em>and <em>Special warnings and precautions for use</em><em> &ndash; Symptoms seen on discontinuation of SEROXAT treatment in adults</em>.</p><p>&nbsp;</p><p>There have been reports of premature birth in pregnant women exposed to paroxetine or other SSRIs, although a causal relationship with drug therapy has not been established.</p><p>&nbsp;</p><p>Observational data have provided evidence of an increased risk (less than two-fold) of postpartum haemorrhage following exposure to SSRIs within one month prior to birth.</p><p>&nbsp;</p><p>Neonates should be observed if maternal use of <em>SEROXAT </em>continues into the later stages of pregnancy, because there have been reports of complications in neonates exposed to <em>SEROXAT </em>or other SSRIs late in the third trimester of pregnancy. However, a causal association with drug therapy has not been confirmed. Reported clinical findings have included: respiratory distress, cyanosis, apnoea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycaemia, hypertonia, hypotonia, hyperreflexia, tremor, jitteriness, irritability, lethargy, constant crying and somnolence. In some instances, the reported symptoms were described as neonatal withdrawal symptoms. In a majority of instances, the complications were reported to have arisen either immediately or soon (&lt;24 hours) after delivery.</p><p>&nbsp;</p><p>Epidemiological studies have shown that the use of SSRIs (including paroxetine) in pregnancy, particularly use in late pregnancy, was associated with an increased risk of persistent pulmonary hypertension of the new-born (PPHN). The increased risk among infants born to women who used SSRIs late in pregnancy was reported to be four to five times higher than observed in the general population (rate of one to two per</p><p>1000 pregnancies).</p><p>&nbsp;</p><p><strong>Lactation</strong></p><p><strong>&nbsp;</strong></p><p>Small amounts of paroxetine are excreted into breast milk. In published studies, serum concentrations in breast-fed infants were undetectable (&lt;2 nanograms/mL) or very low (&lt;4 nanograms/mL). No signs of drug effects were observed in these infants.</p><p>Nevertheless, <em>SEROXAT </em>should not be used during lactation unless the expected benefits to the mother justify the potential risks for the infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical experience has shown that therapy with <em>SEROXAT </em>is not associated with impairment of cognitive or psychomotor function. However, as with all psychoactive drugs, patients should be cautioned about their ability to drive a car and operate machinery.</p><p>&nbsp;</p><p>Although <em>SEROXAT </em>does not increase the mental and motor skill impairments caused by alcohol, the concomitant use of paroxetine and alcohol is not advised.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Some of the adverse experiences listed below may decrease in intensity and frequency with continued treatment and do not generally lead to cessation of therapy. Adverse drug reactions are listed below by system organ class and frequency. Frequencies are defined as very common ( 1/10), common ( 1/100, &lt;1/10), uncommon ( 1/1,000, &lt;1/100), rare ( 1/10,000, &lt;1/1,000), very rare (&lt;1/10,000), including isolated reports. The frequencies of common and uncommon events were generally determined from pooled safety data from a clinical trial population of &gt;8000 paroxetine-treated patients and are quoted as excess incidence over placebo. Rare and very rare events were generally determined from post-marketing data and refer to reporting rate rather than true frequency.</p><p>&nbsp;</p><p><strong>Blood &amp; lymphatic system disorders</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_33b0b0ad-3b78-4237-9fb2-fc23f0f98a16 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Uncommon: abnormal bleeding, predominantly of the skin and mucous membranes. (including ecchymosis and gynaecological bleeding).</p><p>Very rare: thrombocytopenia.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp; Unknown: Lekopenia</p><p>&nbsp;</p><p><strong>Immune system disorders</strong><!--[if supportFields]><b><span style='font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_7bdc8aaf-61b6-4d94-85ae-5183f3ad8a2d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Very rare: severe allergic reactions (including anaphylactoid reactions and angioedema).</p><p>&nbsp;</p><p><strong>Endocrine disorders</strong><!--[if supportFields]><b><span style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_dca055e9-468a-4b0e-ac2d-00d531355657 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Very rare: syndrome of inappropriate anti-diuretic hormone secretion (SIADH).</p><p>&nbsp;</p><p><strong>Metabolism &amp; nutrition disorders</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_e2ee49df-58e6-4ec0-ae9f-781dbf494958 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Common: increases in cholesterol levels, decreased appetite. Rare: hyponatraemia.</p><p>&nbsp;</p><p>Hyponatraemia has been reported predominantly in elderly patients and is sometimes due to syndrome of inappropriate anti-diuretic hormone secretion (SIADH).</p><p><strong>Psychiatric disorders</strong><!--[if supportFields]><b><span style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_7c68e99b-cdb1-4124-8227-8c46742ed60d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Common: somnolence, insomnia, agitation, abnormal dreams (including nightmares). Uncommon: confusion, hallucinations.</p><p>Rare: manic reactions.</p><p>&nbsp;</p><p>These symptoms may be due to the underlying disease.</p><p>&nbsp;</p><p><strong>Nervous system disorders</strong><!--[if supportFields]><b><span style='font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_633ffc62-11c2-4b65-b7ac-3ac4e5937226 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Common: dizziness, tremor, headache. Uncommon: extrapyramidal disorders.</p><p>Rare: convulsions, akathisia, restless legs syndrome (RLS).</p><p>Very rare: serotonin syndrome (symptoms may include agitation, confusion, diaphoresis, hallucinations, hyperreflexia, myoclonus, shivering tachycardia and tremor).</p><p>&nbsp;</p><p>Reports of extrapyramidal disorders including oro-facial dystonia have been received in patients sometimes with underlying movement disorders or who were using neuroleptic medication.</p><p>&nbsp;</p><p><strong>Eye disorders</strong><!--[if supportFields]><b><span style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_0989b631-cd7b-4d6a-84fd-b7eb166de08b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Common: blurred vision.</p><p>Uncommon: mydriasis (<em>see Special warnings and precautions for use</em>).</p><p>Very rare: acute glaucoma.</p><p>&nbsp;</p><p><strong>Cardiac disorders </strong></p><p>Uncommon: sinus tachycardia.</p><p><strong>Vascular disorders</strong></p><p>&nbsp;</p><p>Uncommon: postural hypotension.</p><p>&nbsp;</p><p><strong>Respiratory, thoracic and mediastinal disorders</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_af718889-b477-4220-ba0e-c60e53aaba7d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Common: yawning.</p><p>&nbsp;</p><p><strong>Gastrointestinal disorders</strong><!--[if supportFields]><b><span style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_fcbb5775-25e8-4bf5-ae7e-f7a2924c29dd \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Very common: nausea.</p><p>Common: constipation, diarrhoea, vomiting, dry mouth. Very rare: gastrointestinal bleeding.</p><p>&nbsp;</p><p><strong>Hepatobiliary disorders</strong><!--[if supportFields]><b><span style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_54f5316b-cea9-4938-9de5-9ac04de07c96 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Rare: elevation of hepatic enzymes.</p><p>Very rare: hepatic events (such as hepatitis, sometimes associated with jaundice and/or liver failure).</p><p>&nbsp;</p><p>Elevation of hepatic enzymes has been reported. Post-marketing reports of hepatic events (such as hepatitis, sometimes associated with jaundice, and/or liver failure) have also been received very rarely. Discontinuation of paroxetine should be considered if there is prolonged elevation of liver function test results.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Skin &amp; subcutaneous tissue disorders</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_672f7971-3f66-4c56-93da-0bf408576be4 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Common: sweating. Uncommon: skin rashes.</p><p>Very rare: severe cutaneous adverse reactions (including erythema multiforme, Stevens- Johnson syndrome and toxic epidermal necrolysis), urticaria, photosensitivity reactions.</p><p>&nbsp;</p><p><strong>Renal &amp; urinary disorders</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_469c0e6e-8326-4f53-84c9-cfe690801198 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Uncommon: urinary retention, urinary incontinence.</p><p>&nbsp;</p><p><strong>Reproductive system &amp; breast disorders</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_428fdfc2-362e-4ff5-b75b-10d2ce9956c6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Very common: sexual dysfunction.</p><p>Rare: hyperprolactinaemia/galactorrhoea, menstrual disorders (including menorrhagia, metrorrhagia and amenorrhoea).</p><p>&nbsp;</p><p><strong>General disorders &amp; administration site conditions</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_5c07ace6-b05a-4396-9bd8-5df481a9f7ac \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Common: asthenia, body weight gain. Very rare: peripheral oedema.</p><p>&nbsp;</p><p><strong>Symptoms seen on discontinuation of paroxetine treatment:</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_d4b5de45-6575-4e4f-9567-985681240636 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Common: dizziness, sensory disturbances, sleep disturbances, anxiety, headache. Uncommon: agitation, nausea, tremor, confusion, sweating, diarrhoea.</p><p>&nbsp;</p><p>&nbsp;</p><p>As with many psychoactive medicines, discontinuation of <em>SEROXAT </em>(particularly when abrupt) may lead to symptoms such as dizziness, sensory disturbances (including paraesthesia, electric shock sensations and tinnitus), sleep disturbances (including intense dreams), agitation or anxiety, nausea, headache, tremor, confusion, diarrhoea and sweating. In the majority of patients, these events are mild to moderate and are self- limiting. No particular patient group appears to be at higher risk of these symptoms; it is therefore advised that when <em>SEROXAT </em>treatment is no longer required, gradual discontinuation by dose tapering be carried out (<em>see Dosage and Administration and Special warnings and precautions for use</em>).</p><p>&nbsp;</p><p><strong>Adverse Events from Paediatric Clinical Trials</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_522e88ae-9f8a-406d-b74f-d75ed18589f0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>In paediatric clinical trials the following adverse events were reported at a frequency of at least 2% of patients and occurred at a rate at least twice that of placebo: emotional lability (including self-harm, suicidal thoughts, attempted suicide, crying and mood fluctuations), hostility, decreased appetite, tremor, sweating, hyperkinesia and agitation. Suicidal thoughts and suicide attempts were mainly observed in clinical trials of adolescents with Major Depressive Disorder. Hostility occurred particularly in children with obsessive compulsive disorder, and especially in younger children less than 12 years of age.</p><p>In studies that used a tapering regimen (daily dose decreased by 10 mg/day at weekly intervals to a dose of 10 mg/day for one week), symptoms reported during the taper phase or upon discontinuation of <em>SEROXAT </em>at a frequency of at least 2% of patients and occurred at a rate at least twice that of placebo were: emotional lability, nervousness, dizziness, nausea and abdominal pain (<em>see Special warnings and precautions for use</em>).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_ac4d8d35-521f-472e-8959-7f2715f7805b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB;mso-bidi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-</strong><strong>National Pharmacovigilance centre (NPC)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting hotline: 19999</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa<u> </u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p><strong>-GlaxoSmithKline - Head Office, Jeddah</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel: +966-12-6536666</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: saudi.safety@gsk.com</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GlaxoSmithKline - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: gcc.medinfo@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/<u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms and Signs</strong></p><p><strong>&nbsp;</strong></p><p>A wide margin of safety is evident from available data. Overdose attempts have been reported in patients who took up to 2000 mg alone or in combination with other drugs, including alcohol. Experience of <em>SEROXAT </em>in overdose has indicated that, in addition to those symptoms mentioned under Adverse Reactions, fever, blood pressure changes, involuntary muscle contractions, anxiety and tachycardia have been reported.</p><p>&nbsp;</p><p>Events such as coma or ECG changes have occasionally been reported and very rarely a fatal outcome, but generally when <em>SEROXAT </em>was taken in conjunction with other psychotropic drugs, with or without alcohol.</p><p>&nbsp;</p><p><strong>Treatment</strong></p><p><strong>&nbsp;</strong></p><p>No specific antidote is known.</p><p>&nbsp;</p><p>Treatment should consist of those general measures employed in the management of overdose with any antidepressant. Supportive care with frequent monitoring of vital signs and careful observation is indicated. Patient management should be as clinically indicated, or as recommended by the national poisons centre, where available.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>ATC Code </strong></p><p>&nbsp;</p><p>Anatomical Therapeutic Chemical (ATC) code: N06A B05.</p><p>Pharmacotherapeutic group: Antidepressants &ndash; selective serotonin reuptake inhibitors.</p><p><strong>Mechanism of Action </strong></p><p>&nbsp;</p><p>Paroxetine is a potent and selective inhibitor of serotonin (5-hydroxytryptamine, 5-HT) re-uptake and its antidepressant action and efficacy in the treatment of OCD and panic disorder is thought to be related to its specific inhibition of serotonin re-uptake in brain neurones.</p><p>&nbsp;</p><p>Paroxetine is chemically unrelated to the tricyclic, tetracyclic and other available antidepressants.</p><p>&nbsp;</p><p>Long-term treatment with <em>SEROXAT </em>has shown that antidepressant efficacy is maintained for periods of at least one year.</p><p>&nbsp;</p><p>In a placebo-controlled trial, the efficacy of <em>SEROXAT </em>in the treatment of panic disorder has been maintained for at least one year.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p><strong><em>&nbsp;</em></strong></p><p>Steady state systemic levels are attained by 7 to 14 days after starting treatment and pharmacokinetics do not appear to change during long-term therapy</p><p>&nbsp;</p><p>Paroxetine is well absorbed after oral dosing and undergoes first-pass metabolism.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Metabolism</strong></p><p><strong><em>&nbsp;</em></strong></p><p>The principal metabolites of paroxetine are polar and conjugated products of oxidation and methylation, which are readily cleared. In view of their relative lack of pharmacological activity, it is most unlikely that they contribute to the therapeutic effects of <em>SEROXAT</em>.</p><p>&nbsp;</p><p><strong>Elimination</strong></p><p><strong><em>&nbsp;</em></strong></p><p>The elimination half-life is variable but is generally about one day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Toxicology studies have been conducted in rhesus monkeys and albino rats; in both, the metabolic pathway is similar to that described for humans. As expected with lipophilic amines, including tricyclic antidepressants, phospholipidosis was detected in rats.</p><p>Phospholipidosis was not observed in primate studies of up to one-year duration at doses that were six times higher than the recommended range of clinical doses.</p><p>&nbsp;</p><p>Carcinogenesis: In two-year studies conducted in mice and rats, paroxetine had no tumorigenic effect.</p><p>Genotoxicity: Genotoxicity was not observed in a battery of <em>in vitro </em>and <em>in vivo </em>tests.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Tablet cores: </em>Calcium phosphate (E341), sodium starch glycollate, magnesium stearate (E572).</p><p><em>Tablet coating: </em>hydroxypropyl methylcellulose (E464), titanium dioxide (E171), polyethylene glycol and polysorbate 80 (E433).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no known incompatibilities with <em>SEROXAT</em> tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store SEROXAT below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Tablets:</em>&nbsp;</p><p>Foil blister packs, child-resistant foil blister packs or polypropylene bottles.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific information</p><p>&nbsp;</p><p>&nbsp;</p><p>Not all presentations are available in every country</p><p>&nbsp;</p><p><strong><em>SEROXAT</em></strong> is a trademark owned by or licenced to GSK group of companies.</p><p>&copy; 2024 GSK group of companies., all rights reserved.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by:
Delpharm Poznań Spółka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznan, Poland

Packed by:
Glaxo Saudi Arabia Ltd.*, Jeddah, Kingdom of Saudi Arabia. 

Marketing Authorisation Holder 
Glaxo Saudi Arabia Ltd.* Jeddah, Kingdom of Saudi Arabia.
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia.

*member of the GSK group of companies

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version number: GDS48/IPI33 
Date of issue: 08 December 2021 

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>